

# SEMI ANNUAL RESEARCH REPORT

July - December 2020



## Acknowledgements

The AMPATH Research Program Office is grateful to our sponsors and research partners who contribute to the success of our research program. Thank you to everyone who contributed to this report and our efforts to improve the health of people in Kenya and resource limited settings around the world.

## Editorial Team

Shawn Grinter  
Kara Wools-Kaloustian  
Jepchirchir Kiplagat Kirui  
Winstone Nyandiko  
Michael Scanlon  
Jerry Wagner  
Eunice Walumbe

Copyright © April 2021 – AMPATH Research Program Office

Contacts	
<b>Jepchirchir Kiplagat-Kirui</b> AMPATH Research Network Program Manager (Kenya) AMPATH Center P.O. Box 4606 Eldoret, Kenya <b>Email:</b> <a href="mailto:research.manager@iukenya.org">research.manager@iukenya.org</a> <b>Phone:</b> +254 53 203 3471 <b>Fax:</b> +254 53 206 1992	<b>Jerry Wagner</b> AMPATH Research Network Program Manager (North America) Indiana University Center for Global Health 702 Rotary Circle, RO131 Indianapolis, IN 46202 <b>Email:</b> <a href="mailto:research.manager@iukenya.org">research.manager@iukenya.org</a> <b>Phone:</b> +1-317-274-4176 <b>Fax:</b> +1-317-274-9124
Please visit the AMPATH Research Program website to learn how our research programs are helping improve the health of the Kenyan people. <a href="https://www.ampathkenya.org/research">https://www.ampathkenya.org/research</a>	

## Table of Contents

Vision, Mission, & Values .....	4
Strategic Priorities.....	4
Activities & Achievements in 2020 .....	5
COVID-19.....	6
Grants.....	6
Publications.....	8
Research Project Snapshot .....	9
Appendix - (see AMPATH Research and Training Extramural Grants Table, Bibliography, and Study Reports) .....	10

## Vision, Mission, & Values

---

### Vision

We envision a vibrant, world-class, Kenyan-led community of researchers engaged in the continuous improvement of health globally.

### Mission

Guided by the principle of leading with care, we work in partnership to develop local research talent and to identify, develop and disseminate relevant and timely information to improve the health of underserved populations.

### Values

In our work we embrace:

- Service with humility
- A spirit of collaboration and partnership
- Integrity in relationships
- Mutual respect and mutual benefit in organizational partnerships
- Efforts to eliminate health disparities
- A sustainable infrastructure for research

## Strategic Priorities

---

After internal and external stakeholders' surveys and interviews, the AMPATH Research Program Office (RPO) convened a two-day strategic planning meeting in September 2019 in Eldoret, Kenya. The meeting included more than 40 key research program leaders and stakeholders tasked with reviewing and evaluating the program's strategic priorities and developing a new strategic plan for the next 3 years. The following strategic priorities were identified:

1. Strengthen development of a **well-resourced and sustainable infrastructure for research** that enables the efficient conduct of high-quality research
2. Increase the number of **successful independent investigators** working in collaborative, interdisciplinary research teams by providing better access to high-quality training and mentorship.
3. Enhance **supportive, research-intensive cultures** within the schools and departments of all AMPATH partners
4. **Accelerate growth in relevant, high-yield research initiatives** that will improve policy and strengthen the health systems and communities we serve including Biomedical innovations, Health Economics/ Equity, Population Health, Informatics, and Implementation Science Research.
5. Incorporate research into ongoing efforts to **expand AMPATH innovations to additional underserved populations outside Kenya**

Based on these strategic priorities, the AMPATH RPO created a 2020-2023 work plan with input from key stakeholders and leadership to implement the program's new strategic plan. The work plan was included in a the AMPATH Research [Semi-Annual Report July – December 2019](#).

## Activities & Achievements in 2020

---

In 2020, the AMPATH Research Program made progress in a number of key areas in line with our strategic plan:

**Training and Mentoring** – In 2020, the AMPATH Research Program conducted a comprehensive training and mentoring needs assessment at AMPATH (the final Training Needs Assessment Report was included in Appendix A of the previous [Semi-Annual Report January – June 2020](#)). Following the needs assessment, the AMPATH Research Program began developing training and mentoring programs for investigators and research staff. To support mentorship and grow the pipeline of investigators, a mentorship program is being designed in collaboration with leadership from Moi University Schools of Medicine and Public Health, which will include training for mentors and mentees using synchronous and asynchronous platforms. To support research staff, an onboarding course for new research coordinators and assistants is under development, which will provide new staff information on the AMPATH Research Program, its policies and procedures, various research offices, and best practices for research. We hope that the mentorship program and onboarding training will be launched mid-year 2021.

**Research Working Groups** – AMPATH Research Working Groups (ARWG) were established to be an interface between clinical care and research, a platform for mentorship and collaboration particularly between Kenyan and North American investigators, and to ensure equitable access to research resources. Following a 2019 SWOT analysis, several challenges were identified by investigators in meeting these objectives, and in 2020 the AMPATH Research Program undertook a revision to the standard terms of reference for ARWG. This includes requiring ARWG to annually report on milestones and achievements in 5 core areas, advising ARWG to review their current governance structures and to promote leadership opportunities for younger investigators, and creating a two-tiered review process for proposals to streamline processes for review and approval of proposals by ARWG. New terms of references were discussed and agreed to by ARWG leaders by the end of 2020 and ARWG are in the process of instituting these changes that will be finalized by mid-year 2021.

**AMPATH Facility Fee** – The AMPATH Research Program represents a robust and unique collaborative research infrastructure, including the AMPATH Research Program Office, Research and Sponsored Projects Office, Moi/MTRH Institutional Research and Ethics Committee, and research cores that offer expertise and services in laboratory and biobanking, informatics, data management and biostatistics, and qualitative research. To support this infrastructure, the AMPATH Research Facility Fee was established for research projects that is based on total % FTE of North American investigators (see [SOP for Research Project and Grant Proposal Development](#)) and is currently administered by the Indiana University Center for Global Health. In 2020, the AMPATH Research Program began a process of revising the AMPATH Research Facility Fee in an attempt to simplify the administration of the fee by moving it to Moi/MTRH and use a fee calculation model that more accurately represents the use of resources for a particular project while not increasing overall costs of doing research at AMPATH. A new facility fee policy should be rolled out in 2021.

**Collaboration with Indiana CTSI** – The AMPATH Research Program continues to expand its footprint through engagement with stakeholders through the Indiana CTSI. In December 2020, an [Indiana CTSI Reciprocal Innovation Stakeholders meeting](#) was co-hosted by Co-Directors of Research Kara Wools-Kaloustian and Winstone Nyandiko. The virtual meeting was designed to bring together investigators in Indiana and East Africa to identify health priorities of the upcoming [Indiana CTSI Global Health Reciprocal Innovation Demonstration and Planning Grants](#) and create opportunities for new collaborations in reciprocal innovation. The Demonstration and Planning grant RFAs were released in early 2021.

**AMPATH Research Replication** – Drs. Wools-Kaloustian and Winstone Nyandiko co-chair the AMPATH Research Replication Working Group, which was constituted in October 2020 to support the replication of AMPATH in Ghana (led by New York University and the University of Development Studies) and in México (led by University of Texas Austin and Benemérita Universidad Autónoma de Puebla). Drawing on over 30 years of collaboration and partnership in Kenya, the group is developing various resources such as research infrastructure assessment tools and best practices that can be adapted by replication partners. The group will also serve as a unique platform to connect Kenyan investigators and research leaders with new partners in Ghana and México for collaborative research projects and developing research infrastructure.

**AMPATH Research Newsletter** – To stay updated on important activities at the AMPATH Research Program as well as new grant and funding opportunities, published articles from AMPATH investigators, and calendar events such as the AMPATH Works in Progress meetings, please be sure to subscribe to the AMPATH Research Newsletter. The Newsletter was re-launched in 2020 as a monthly publication. Contact the AMPATH Research Program Office ([research.manager@iukenya.org](mailto:research.manager@iukenya.org)) to subscribe.

## COVID-19

---


Kenya reported its first case of COVID-19 on March 15, 2020, and the AMPATH Research Program provided continued guidance throughout the year to AMPATH investigators and research teams for the safe conduct of research. Following a program-wide suspension of in-person research activities (with the exception of clinical trials and other activities that may compromise research participant safety) on March 18, the AMPATH Research Program issued comprehensive guidelines for the safe re-opening of in-person research on July 1 (see [Return to Work Policy for AMPATH Research Program Staff](#) and the [AMPATH Research Program – COVID-19 Restart Checklist](#)). Infections among research staff and participants remained low and by the end of the reporting period, research activities were fully open provided that investigators and teams abided by guidance issues by RPO and local and national public health officials. Several AMPATH investigators started COVID-19 related research projects. Results of these studies are forthcoming, and we look forward to sharing their findings in the next semi-annual report.

## Grants


---

Despite challenges associated with COVID-19, AMPATH affiliated investigators received US\$ 16.2 million in extramural funding for research and training activities in 2020. The amount awarded in 2020 increased AMPATH's cumulative total of research and training awards to over US\$ 187 million (Figure 1). Consistent with previous years, the majority of funding for research and training activities in the US National Institutes of Health, which in 2020 accounted for over 80% of funding (Figure 2). See Appendix A. AMPATH Research & Training Extramural Awards Table, 2020, for a summary of projects funded this year 2020.

**Figure 1: Cumulative AMPATH Research and Training Grant Dollars (US \$) 1998 - 2020**



**Figure 2: AMPATH Research Funding Received by Sponsor in 2020**




## Publications

---

AMPATH investigators published a record 189 articles in 2020, increasing the total number of AMPATH publications to 970 since the beginning of the partnership in 1989 (see Figure 3 for publications by year between 2011 and 2020). AMPATH investigators continued to produce publications in a wide range of research in basic and clinical science research, epidemiology, implementation science, health services and systems research, and bioethics. The Moi University Clinical Research Centre was one of 11 AIDS Clinical Trials Group sites in Brazil, Kenya, Malawi, South Africa, Uganda, and Zimbabwe to participate in a three-arm, randomized, non-inferiority trial for the treatment of advanced AIDS-associated Kaposi sarcoma, which was published in April 2020 in *The Lancet*. In addition to research in the area of HIV, publications in the areas of maternal and child health, substance use, mental health, and non-communicable diseases such as hypertension and heart disease illustrate the variety of research being conducted at AMPATH. A bibliography of publications in 2020 can be found in Appendix B. Bibliography.

**Figure 3: Articles Published by AMPATH Affiliated Investigators, 2011-2020**





## Research Project Snapshot

---

A total of 61 research projects at AMPATH completed AMPATH Research Program Office requests for updates on their study and submitted information. Individual study reports provided by the projects' Principal Investigator(s) or their designee that describes the study's specific aims, sites, project period, sponsors, and project status are available in Appendix C. Study Reports.

### *Institutional affiliation of Principal Investigators*

Studies were led by principal investigators at various AMPATH affiliated institutions including Moi University (23 studies) or Moi Teaching and Referral Hospital (1 study), Indiana University (14 studies), Mount Sinai (7 studies), Duke University (4 studies), Brown University (5 studies), New York University (2 studies), as well as several non-AMPATH Consortium member institutions (University of California – Riverside, Albert Einstein College of Medicine, University of Alabama, University of Washington, and Karolinska Institute, with each institution leading 1 study, respectively).

### *Study characteristics*

Most research employed a prospective study design (72%), while 18% of studies were cross-sectional and 8% were retrospective. Most studies took place in a clinical setting (57%), although an increasing number of studies were also based in the community, with 31% reporting that their study's primary setting was both clinic and community and 8% of reporting that their study was entirely community-based.

### *Geographic distribution of study activities*

Over half of studies (54%) had activities at Moi Teaching and Referral Hospital (MTRH) or in other parts of Uasin Gishu County (47%), however, many studies reported activities in other Counties illustrating the reach of AMPATH Research Program activities across many parts of western Kenya. Among the most frequently cited study locations outside of Uasin Gishu included Trans Nzoia County (39% of studies), Bungoma County (38%), Busia County (33%), Kakamega County (15%), Nandi County (15%), and Kisumu County (13%), among others.

### *Study status*

The majority of studies were either still open to enrollment and with participants receiving research-related intervention or follow up (41% of studies) or ongoing but in data analysis only (33%). There were a number of studies (15%) that reported study activities had not yet begun.

*Appendix - (see AMPATH Research and Training Extramural Grants Table, Bibliography, and Study Reports)*

---

## Table of Contents - Appendix

Appendix A. AMPATH Research and Training Extramural Grants Table, 2020	1
Appendix B. Bibliography	4
Appendix C. Study Reports	17
A cluster randomized trial of 'Teach HADITHI' teacher training intervention to reduce classroom HIV-related stigma in Kenya.....	17
A longitudinal survey study of the impact of COVID-19 preparedness and response efforts on people living with HIV in East Africa.....	17
A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants with PTSD Taken Daily at Bedtime.....	18
A prospective cohort among people living with HIV (IeDEA-SRN).....	18
A randomized experiment of malaria diagnostic testing and conditional subsidies to target ACTs in the retail sector: the TESTsmART trial AIM 1.....	19
A randomized experiment of malaria diagnostic testing and conditional subsidies to target ACTs in the retail sector: the TESTsmART trial AIM 2.....	20
A5300B/I2003B/PHOENix Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENix MDR-TB).....	20
A5381 Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or with Rifampicin-Containing TB Treatment.....	21
Addressing bioethical research gaps in research with young people living with HV in Kenya.....	22
Addressing HIV drug resistance research gaps in a cohort of perinatally infected Kenyan children and adolescents.....	22
APPROACH.....	23
Bridging Income Generation with Group Integrated Care (BIGPIC).....	23
Chamas for Change: Adapting a community-based peer-support and health education model for pregnant and parenting adolescents in Kenya.....	24
Chamas for Change: Validating an integrated community-based strategy of peer support in pregnancy and infancy.....	25
Clinical Assessment for Retention and Engagement (CARE Study).....	25
Comparison of Nutritional status of children aged 5 to 59 months in community based education and service (COBES)-AMPATH and non AMPATH centres post covid-19.....	26

Developing Capacity of Moi Teaching and Referral Hospital / Moi University Institutional Research Ethics Committee (MTRH/MU IREC), Kenya to Prevent and Manage Research Misconduct. ....	26
EA-IeDEA ACE Study .....	27
EA-IeDEA Main .....	28
EA-IeDEA Networks In Kenya .....	28
EA-IeDEA NIDA Study .....	29
EA-IeDEA - PHQ 9 Study .....	30
EA-IeDEA Syndemics .....	30
Enhancing Preventive Therapy of Malaria in children with Sickle Cell Anemia (SCA) in East Africa (EPiTOMISE) .....	31
Ethnic Specific Risk Stratification in Early Pregnancy for Identifying Mothers at Risk of Gestational Diabetes Mellitus in Eldoret Kenya .....	31
Evaluating reproductive and HIV outcomes and decision-making among HIV-positive women on dolutegravir: A prospective, observational cohort at AMPATH, Kenya .....	32
Evaluation of Chronic Hypoxemia from Cardiopulmonary Disease Among Patients Admitted to a Referral Hospital in Western Kenya and Their Perspectives on Oxygen Use .....	33
Feasibility and acceptability of Enhanced Patient Care (EPC) for adult HIV patients with unsuppressed viral loads in western Kenya .....	33
Harambee: Integrated Community-Based HIV/NCD Care & Microfinance Groups in Kenya .....	34
HIV-related outcomes at the AMPATH Drug Resistance Clinic in Kenya .....	34
Impact of COVID-19 on adolescents living with HIV in Kenya .....	35
Implementing a Model of Improved Care for Infectious Diseases and Antibiotic Stewardship across Multiple Levels of the Health System in Western Kenya .....	36
Improving Estimates of Mother-to-Child Transmission in Western Kenya: A Mixed Methods Prospective Cohort Study - Plus (IeDEA PMTCT Plus study) .....	36
Making Inroads to Strengthen the Health of Adolescents .....	37
Maternal Newborn Health Registry .....	37
Measuring adverse pregnancy and newborn outcomes (MANGO); An IeDEA collaboration study .....	38
Mobile Mental Health Monitoring and Support for Adolescents with HIV in Kenya .....	39
NeInnovate Collaborative Consortium .....	39
Neurodevelopmental Screening in Children Born to HIV-Infected Mothers in Kenya .....	40
NEUROPSYCHIATRIC GENETICS OF AFRICAN POPULATIONS - PSYCHOSIS (NEUROGAP-P) .....	40

Optimizing HIV treatment monitoring strategies under resource constraints.....	41
Optimizing Linkage and Retention to Hypertension Care in Rural Kenya (LARK).....	42
Patient-Centered Disclosure Intervention for HIV-Infected Children, Helping AMPATH Disclose Information and Talk about HIV Infection (HADITHI) .....	42
Prevalence and Impact of SARS-CoV-2 Among Pregnant Women in Low- and Middle- income Countries.....	43
Prevalence of hypertension among postpartum women with preeclampsia (PET) in Kenya: a prospective cohort study .....	44
Prevention of maternal and neonatal death/infections with a single oral dose of Azithromycin in women in labor (in low- and middle-income countries): a Randomized Controlled Trial (The A-PLUS study).....	44
Prevention of maternal and neonatal death/infections with a single oral dose of Azithromycin in women in labor (in low- and middle-income countries): a Randomized Controlled Trial (The A-PLUS study).....	45
Prospective study of Lopinavir based ART for HIV Infected children Globally (LIVING study) 2 .....	45
PT4A (Peers and Technology for Adherence, Access, Accountability, and Analytics) .....	46
SAFI (Stigma in AIDS Family Inventory) Validation Study .....	47
Spatial scales of Plasmodium falciparum generations; implications for elimination .....	47
Stated Preference Analysis to Refine PMTCT Service Delivery in Kenya (SPARK) study .....	48
Strengthening Referral Networks for Management of Hypertension Across the Health System (STRENGTHS) .....	49
The Effect of Weekly Text Messaging to Improve Retention across the PMTCT Cascade for Pregnant HIV- infected Women: Study Protocol for a Randomized Controlled Trial (WelTel PMTCT).....	49
THE IMPACT OF USING HEMOTYPE SCTM IN SCREENING FOR SICKLE CELL DISEASE IN NEONATES, INFANTS, AND CHILDREN UNDER FIVE YEARS OF AGE IN A RESOURCE LIMITED SETTING.....	50
The Prevalence of and Risk Factors for Non-Alcoholic Fatty Liver Disease in Kenya .....	51
Virologic Treatment Failure and Drug Resistance in HIV-infected Kenyan Children .....	51
World Bleeding Disorders Registry (WBDR) .....	52

## Appendix A. AMPATH Research and Training Extramural Grants Table, 2020

Title	PIs	Prime	Sponsor	Amount (USD)*	Project Dates	Link
A case study of integrated delivery of selected non-communicable diseases in Kenya	Jemima Kamano	Moi Teaching and Referral Hospital	World Bank	775,000	2/1/2018 - 3/31/2021	<a href="#">Click here.</a>
Addressing HIV Drug Resistance Research Gaps in a Cohort of Perinatally Infected Kenyan Children and Adolescents	Rami Kantor, Winstone Nyandiko, Rachel Vreeman	Miriam Hospital	NIAID	967,487	6/27/2019 - 5/31/2024	<a href="#">Click here.</a>
Addressing HIV Drug Resistance Research Gaps in a Cohort of Perinatally Infected Kenyan Children and Adolescents [Supplement: Addressing Bioethical Research Gaps with Young People Living with HIV in Kenya]	Rami Kantor, Winstone Nyandiko, Rachel Vreeman	Miriam Hospital	NIAID	166,607	6/27/2019 - 5/31/2024	<a href="#">Click here.</a>
BREATHER Plus - A randomised open-label 3-arm, 96-week trial evaluating the efficacy, safety and acceptability of weekends off dolutegravir-based antiretroviral therapy (ART) and monthly long-acting injectable ART compared to daily dolutegravir-based ART in virologically suppressed HIV-infected children and adolescents in sub-Saharan Africa	Abraham Siika	Baylor College of Medicine Children's Foundation - Uganda	European & Developing Countries Clinical Trials Partnership (EDCTP2)	154,635	1/1/2020 - 12/31/2025	<a href="#">Click here.</a>
Brown/Moi Training Program for the Prevention of HIV related Cervical Cancer	Susan Cu-Uvin, Omenge Orang'u	Brown University	FIC / NCI	300,572	4/16/2019 - 3/31/2024	<a href="#">Click here.</a>
Brown/Moi Training Program for the Prevention of HIV related Cervical Cancer – Supplement 1	Susan Cu-Uvin	Brown University	FIC / NCI	75,000	4/19/2019 - 3/31/2024	<a href="#">Click here.</a>

Developing an Instrument to Assess Adolescent Risk for Disengagement from HIV Care	Leslie Enane	Indiana University	NICHD	156,739	8/1/2018 - 7/31/2023	<a href="#">Click here.</a>
East Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA) Regional Consortium	Kara Wools-Kaloustian, Constantin Yiannoutsos	Indiana University	NIAID	3,826,050 (includes non-AMPATH sites)	8/5/2006 - 7/31/2021	<a href="#">Click here.</a>
East Africa International Epidemiologic Databases to Evaluate AIDS (IeDEA) Regional Consortium – Supplement 1	Kara Wools-Kaloustian, Constantin Yiannoutsos	Indiana University	NIAID	150,000	8/5/2006 - 7/31/2021	<a href="#">Click here.</a>
Estimating the Cascade of HIV Care Under Incomplete Outcome Ascertainment	Giorgos Bakoyannis, Lameck Diero	Indiana University	NIAID	196,875	6/17/2019 - 5/31/2021	<a href="#">Click here.</a>
Feasibility and acceptability of Enhanced Patient Care (EPC) for adult HIV patients with unsuppressed viral loads in western Kenya	Juddy Wachira	Moi University	FIC	110,641	9/15/2018 - 1/31/2023	<a href="#">Click here.</a>
Global Network for Women’s and Children’s Health Research	Edward Liechty, Sherri Bucher, Fabian Esamai	Indiana University	NICHD	610,185	5/25/2013 - 5/31/2023	<a href="#">Click here.</a>
Harambee: Integrated Community-Based HIV/NCD Care & Microfinance Groups In Kenya	Omar Galarraga, Becky Genberg, Juddy Wachira	Brown University	NIMH	500,816	7/5/2019 - 4/30/2024	<a href="#">Click here.</a>
HIV Drug Resistance, Monitoring and Transmission	Rami Kantor, Lameck Diero, Nathan Buziba	Miriam Hospital	NIAID	138,943	3/1/2018 - 2/28/2023	<a href="#">Click here.</a>
Immune Exhaustion In Perinatal HIV Infection	Alka Khaitan	Indiana University	NICHD	315,859	4/1/2020 - 3/31/2022	<a href="#">Click here.</a>
Improving the care cascade for HIV associated Kaposi Sarcoma in Sub-Saharan Africa	Esther Freeman, Naftali Busakhala	Massachusetts General Hospital	NIAID	199,279	7/19/2018 - 6/30/2023	<a href="#">Click here.</a>

Investigating interactions between efavirenz-based antiretroviral therapy and contraceptive implants	Rena Patel, Beatrice Jakait	Univesity of Washington	NIAID	147,927	7/1/2015 - 6/3/2020	<a href="#">Click here.</a>
Malaria Chemoprevention in Children with Sickle Cell Anemia in Western Kenya	Steve Taylor, Festus Njuguna	Duke University	NHLBI	518,962	6/1/2016 - 2/28/2022	<a href="#">Click here.</a>
Malaria diagnostic testing and conditional subsidies to target ACTs in the retail sector: the TESTsmART trial	Wendy Prudhomme-O'Meara	Duke University	NIAID	894,519	9/14/2018 - 8/31/2023	<a href="#">Click here.</a>
Neurodevelopmental screening in children born to HIV-infected mothers in Kenya	Megan McHenry, Eren Oyungu	Indiana University	NIMH	181,595	9/21/2018 - 8/31/2022	<a href="#">Click here.</a>
Once Bitten; A longitudinal, observational study of Succesful Malaria Parasite transmission events between humans and Mosquitos	Wendy Prudhomme-O'Meara, Steve Taylor, Andrew Obala	Duke University	NIAID	600,701	7/16/2019 - 6/30/2024	<a href="#">Click here.</a>
PT4A (Peers and Technology For Adherence, Access, Accountability, and Analytics)	Rajesh Vedanthan, Sonak Pastakia, Benson Njuguna	New York University	NHLBI	697,887	9/25/2020 - 8/31/2021	<a href="#">Click here.</a>
Smartphone-Based Diagnostic for HIV Self-Testing	Jacqueline Linnes, Ronald Tonui	Purdue University	NIAID	370,285	8/6/2018 - 7/31/2021	<a href="#">Click here.</a>
Strengthening Referral Networks for Management of Hypertension Across the Health System (STRENGTHS)	Constantine Akwanalo, Jemima Kamano	Moi University	NHLBI	321,760	9/1/2017 - 5/31/2022	<a href="#">Click here.</a>
The East Africa Consortium For HPV and Cervical Cancer In Women Living With HIV/AIDS	Patrick Loehrer, Darron Brown, Miriam Nakalembe, Omenge Orango	Indiana University	NCI	995,284	9/7/2020 - 8/31/2025	<a href="#">Click here.</a>
Training in STIs and Infections of Global Health Significance	Kara Wools-Kaloustian	Indiana University	NIAID	210,437	7/1/2001 - 8/31/2021	<a href="#">Click here.</a>



## Appendix B. Bibliography

---

The following bibliography includes AMPATH research publications that were published in 2020. A complete bibliography of AMPATH research publications published since 1989 along with full text articles is available online through the AMPATH Research Member Access [Portal](#).

1. Abila AW, Nditika ME, Kipkemoi RD, Ondigo S, Khwa-Otsyula BO. Primary repair of esophageal perforation: Case report. *Int J Surg Case Rep.* 2020;71:159-62.
2. Ampamya S, Kitayimbwa JM, Were MC. Performance of an open source facial recognition system for unique patient matching in a resource-limited setting. *Int J Med Inform.* 2020;141:104180.
3. Aziz A, Saleem S, Nolen TL, Pradhan NA, McClure EM, Jessani S, et al. Why are the Pakistani maternal, fetal and newborn outcomes so poor compared to other low and middle-income countries? *Reprod Health.* 2020;17(Suppl 3):190.
4. Bauserman M, Nowak K, Nolen TL, Patterson J, Lokangaka A, Tshefu A, et al. The relationship between birth intervals and adverse maternal and neonatal outcomes in six low and lower-middle income countries. *Reprod Health.* 2020;17(Suppl 2):157.
5. Bauserman M, Thorsten VR, Nolen TL, Patterson J, Lokangaka A, Tshefu A, et al. Maternal mortality in six low and lower-middle income countries from 2010 to 2018: risk factors and trends. *Reprod Health.* 2020;17(Suppl 3):173.
6. Chammartin F, Dao Ostinelli CH, Anastos K, Jaquet A, Brazier E, Brown S, et al. International epidemiology databases to evaluate AIDS (IeDEA) in sub-Saharan Africa, 2012-2019. *BMJ Open.* 2020;10(5):e035246.
7. Chirchir LK, Aruasa WK, Chebon SK. Determining Role of Social Factors in Adoption of Electronic Health Records by Nurses. *Stud Health Technol Inform.* 2020;272:111-4.
8. Chitsike I, Paintsil V, Sung L, Njuguna F, Mavinkurve-Groothuis A, Kouya F, et al. Working Together to Build a Better Future for Children With Cancer in Africa. *JCO Glob Oncol.* 2020;6:1076-8.
9. Collaboration CIPHER. Outcomes of second-line antiretroviral therapy among children living with HIV: a global cohort analysis. *J Int AIDS Soc.* 2020;23(4):e25477.
10. Collaboration IACIEC. All-cause mortality after antiretroviral therapy initiation in HIV-positive women from Europe, Sub-Saharan Africa and the Americas. *Aids.* 2020;34(2):277-89.
11. Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort. Outcomes of second-line antiretroviral therapy among children living with HIV: a global cohort analysis. *J Int AIDS Soc.* 2020;23(4):e25477.
12. Dedhia PH, Stoeckl EM, McDow AD, Saruni S, Schneider DF, Long KL. Preoperative surgeon-performed ultrasound of massive thyroid goiter in rural Kenya. *American journal of surgery.* 2020.
13. Desmond S, Ciaranello AL, Malateste K, Musick B, Patten G, Vu AT, et al. Age-specific mortality rate ratios in adolescents and youth aged 10-24 years living with perinatally versus non-perinatally-acquired HIV. *Aids.* 2020.
14. Desmond S, Neilan AM, Musick B, Patten G, Chokephaibulkit K, Edmonds A, et al. Time-varying age- and CD4-stratified rates of mortality and WHO stage 3 and stage 4 events in children, adolescents and youth 0 to 24 years living with perinatally acquired HIV, before and after

- antiretroviral therapy initiation in the paediatric IeDEA Global Cohort Consortium. *J Int AIDS Soc.* 2020;23(10):e25617.
15. Dinssa F, Nyabinda N, Byrnes D, Ndinya C, Merchant E, Simon J. Performances of Vegetable Amaranth Entries in Yield and Nutrient Contents in Tanzania and Kenya, and Variety Release. *Journal of Medicinally Active Plants.* 2020;9(3):181-94.
  16. Drame I, Kahaleh A, Connor S, Seo SW, Jonkman LJ, Schellhase E, et al. An Ethics-based approach to Global Health Research Part 3: Emphasis on Partnership Funding. *Res Social Adm Pharm.* 2020;16(11):1588-96.
  17. Du RY, Thiong'o GM, LoPresti MA, Mohan NK, Dewan MC, Lepard J, et al. Pediatric Neurosurgery in East Africa: An Education and Needs-Based Survey. *World Neurosurg.* 2020;141:e374-e82.
  18. Edens E. Approaches to Conducting Qualitative Research on Western-Based Research Misconduct Policy in Non-Western Countries. London 2020. Available from: <https://methods.sagepub.com/case/approaches-conducting-research-misconduct-non-western-countries>.
  19. Edward A, Krishnan A, Etyyang G, Jung Y, Perry HB, Ghee AE, et al. Can people-centered community-oriented interventions improve skilled birth attendance? Evidence from a quasi-experimental study in rural communities of Cambodia, Kenya, and Zambia. *BMC Pregnancy Childbirth.* 2020;20(1):514.
  20. Elias HE, Amisi JA. Twin pregnancy in a bicornuate uterus in rural Kenya: A case report for accidental discovery and successful delivery. *Afr J Prim Health Care Fam Med.* 2020;12(1):e1-e4.
  21. Embleton L, Di Ruggiero E, Logie CH, Ayuku D, Braitstein P. Piloting an evidence-based intervention for HIV prevention among street youth in Eldoret, Kenya. *Int J Public Health.* 2020;65(4):433-43.
  22. Embleton L, Di Ruggiero E, Logie CH, Ayuku D, Braitstein P. Improving livelihoods and gender equitable attitudes of street-connected young people in Eldoret, Kenya: Results from a pilot evidence-based intervention. *Health Soc Care Community.* 2020.
  23. Embleton L, Shah P, Gayapersad A, Kiptui R, Ayuku D, Braitstein P. Characterizing street-connected children and youths' social and health inequities in Kenya: a qualitative study. *International Journal for Equity in Health.* 2020;19(1):147.
  24. Enane LA, Apondi E, Toromo J, Bosma C, Ngeresa A, Nyandiko W, et al. "A problem shared is half solved" - a qualitative assessment of barriers and facilitators to adolescent retention in HIV care in western Kenya. *AIDS Care.* 2020;32(1):104-12.
  25. Engelman D, Yoshizumi J, Hay RJ, Osti M, Micali G, Norton S, et al. The 2020 International Alliance for the Control of Scabies Consensus Criteria for the Diagnosis of Scabies. *Br J Dermatol.* 2020;183(5):808-20.
  26. English M, Strachan B, Esamai F, Ngwiri T, Warfa O, Mburugu P, et al. The paediatrician workforce and its role in addressing neonatal, child and adolescent healthcare in Kenya. *Arch Dis Child.* 2020;105(10):927-31.
  27. Esamai F, A M, Tabu J, Nangami M, Were e, Ayuku D. Trends in maternal and child health outcomes in a health systems intervention: a case of Obekai dispensary in western Kenya. *Journal of Global Health Reports.* 2020.

28. Figueroa L, McClure EM, Swanson J, Nathan R, Garces AL, Moore JL, et al. Oligohydramnios: a prospective study of fetal, neonatal and maternal outcomes in low-middle income countries. *Reprod Health*. 2020;17(1):19.
29. Freeman E, McMahan D, Semeere A, Byakwaga H, Laker-Oketta M, Wenger M, et al. Beyond T Staging in the Treat All Era: Capturing the Severity and Heterogeneity of Kaposi's Sarcoma in East Africa. *medRxiv*. 2020;1.
30. Freeman EE, Busakhala N, Regan S, Asirwa FC, Wenger M, Seth D, et al. Real-world use of chemotherapy for Kaposi's sarcoma in a large community-based HIV primary care system in Kenya. *BMC Cancer*. 2020;20(1):71.
31. Garces A, MacGuire E, Franklin HL, Alfaro N, Arroyo G, Figueroa L, et al. Looking beyond the numbers: quality assurance procedures in the Global Network for Women's and Children's Health Research Maternal Newborn Health Registry. *Reprod Health*. 2020;17(Suppl 2):159.
32. Gayapersad A, Embleton L, Shah P, Kiptui R, Ayuku D, Braitstein P. Using a sociological conceptualization of stigma to explore the social processes of stigma and discrimination of children in street situations in western Kenya. *Child Abuse Negl*. 2020:104803.
33. Gesicho MB, Babic A, Were MC. K-Means Clustering in Monitoring Facility Reporting of HIV Indicator Data: Case of Kenya. *Stud Health Technol Inform*. 2020;272:143-6.
34. Gesicho MB, Babic A, Were MC. Health Facility Ownership Type and Performance on HIV Indicator Data Reporting in Kenya. *Stud Health Technol Inform*. 2020;270:1301-2.
35. Gesicho MB, Were MC, Babic A. Data cleaning process for HIV-indicator data extracted from DHIS2 national reporting system: a case study of Kenya. *BMC Med Inform Decis Mak*. 2020;20(1):293.
36. Giusto A, Ayuku D, Puffer E. An intervention to reduce alcohol use and improve family engagement for fathers in low-resource settings: Development and feasibility testing in Kenya. *OSF Preprints*. 2020.
37. Giusto A, Green EP, Simmons RA, Ayuku D, Patel P, Puffer ES. A multiple baseline study of a brief alcohol reduction and family engagement intervention for fathers in Kenya. *J Consult Clin Psychol*. 2020;88(8):708-25.
38. Goudar SS, Goco N, Somannavar MS, Kavi A, Vernekar SS, Tshetu A, et al. Institutional deliveries and stillbirth and neonatal mortality in the Global Network's Maternal and Newborn Health Registry. *Reprod Health*. 2020;17(Suppl 3):179.
39. Green EP, Lai Y, Pearson N, Rajasekharan S, Rauws M, Joerin A, et al. Expanding Access to Perinatal Depression Treatment in Kenya Through Automated Psychological Support: Development and Usability Study. *JMIR Form Res*. 2020;4(10):e17895.
40. Gudu E, Obonyo M, Omballa V, Oyugi E, Kiilu C, Githuku J, et al. Factors associated with malnutrition in children < 5 years in western Kenya: a hospital-based unmatched case control study. *BMC Nutr*. 2020;6:33.
41. Harezlak J, Sarwat S, Wools-Kaloustian K, Schomaker M, Balestre E, Law M, et al. PS-SiZer map to investigate significant features of body-weight profile changes in HIV infected patients in the leDEA Collaboration. *PLoS ONE*. 2020;15(5):e0220165.
42. Harrison MS, Garces A, Figueroa L, Esamai F, Bucher S, Bose C, et al. Caesarean birth by maternal request: a poorly understood phenomenon in low- and middle-income countries. *International health*. 2020.

43. Harrison MS, Garces AL, Goudar SS, Saleem S, Moore JL, Esamai F, et al. Cesarean birth in the Global Network for Women's and Children's Health Research: trends in utilization, risk factors, and subgroups with high cesarean birth rates. *Reprod Health*. 2020;17(Suppl 3):165.
44. Harunani S, Imbaya K, Kuremu T. Non-traumatic abdominal surgical emergencies in children. *Annals of African Surgery*. 2020;17(1).
45. Hedestig M. Back to Basics in Eldoret, Kenya. Partnerships for sustainable health care systems—the International Medical Program approach. 2020:127.
46. Hoffman MK, Goudar SS, Kodkany BS, Metgud M, Somannavar M, Okitawutshu J, et al. Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial. *Lancet*. 2020;395(10220):285-93.
47. Humphrey JM, Mpofo P, Pettit AC, Musick B, Carter EJ, Messou E, et al. Mortality Among People With HIV Treated for Tuberculosis Based on Positive, Negative, or No Bacteriologic Test Results for Tuberculosis: The IeDEA Consortium. *Open Forum Infect Dis*. 2020;7(1):ofaa006.
48. IeDEA and COHERE in EuroCoord Cohort Collaboration. All-cause mortality after antiretroviral therapy initiation in HIV-positive women from Europe, Sub-Saharan Africa and the Americas. *Aids*. 2020;34(2):277-89.
49. Jaguga F, Kiburi SK. Reducing alcohol misuse during the COVID-19 pandemic in Kenya. *Lancet Psychiatry*. 2020;7(11):935-6.
50. Jaguga F, Kwobah E. A review of the public sector substance use disorder treatment and prevention systems in Kenya. *Subst Abuse Treat Prev Policy*. 2020;15(1):47.
51. Jaguga F, Kwobah E. Mental health response to the COVID-19 pandemic in Kenya: a review. *Int J Ment Health Syst*. 2020;14:68.
52. Jedy-Agba E, Joko WY, Liu B, Buziba NG, Borok M, Korir A, et al. Trends in cervical cancer incidence in sub-Saharan Africa. *Br J Cancer*. 2020;123(1):148-54.
53. Jesson J, Desmonde S, Yiannoutsos CT, Patten G, Malateste K, Duda SN, et al. Weight-for-age distributions among children with HIV on antiretroviral therapy in the International epidemiology Databases to Evaluate AIDS (IeDEA) multiregional consortium. *BMC Res Notes*. 2020;13(1):249.
54. Jones L, Gathu C, Szkwarko D, Mucheru S, Amin N, Amisi JA, et al. Expanding Point-of-Care Ultrasound Training in a Low- and Middle-Income Country: Experiences From a Collaborative Short-Training Workshop in Kenya. *Fam Med*. 2020;52(1):38-42.
55. Kafu C, Wachira J, Braitstein P, Wilson I, Koech B, Kamene R, et al. Provider perspectives on the role of the patient as an active participant in HIV care. *Global public health*. 2020:1-11.
56. Kalbarczyk A, Harrison M, Sanguineti MCD, Wachira J, Guzman CAF, Hansoti B. Practical and Ethical Solutions for Remote Applied Learning Experiences in Global Health. *Ann Glob Health*. 2020;86(1):103.
57. Kalbarczyk A, M H, MCD S, J W, CAF G, B H. Practical and Ethical Solutions for Remote Applied Learning Experiences in Global Health. *Ann Glob Health*. 2020;86(1):103.
58. Kamaara E, Kong C, Campbell M. Prioritising African perspectives in psychiatric genomics research: Issues of translation and informed consent. *Developing World Bioethics*. 2020;20(3):139-49.

59. Karwa R, Miller M, Schellhase E, Tran T, Manji I, Njuguna B, et al. Evaluating the Impact of a 15-year Academic Partnership to Promote Sustainable Engagement, Education, and Scholarship in Global Health. *Journal of the American College of Clinical Pharmacy*. 2020.
60. Kelly A, Mitra S, Elung'at J, Songok J, Jackson S, Christoffersen-Deb A. Can the financial burden of being a community health volunteer in western Kenya exacerbate poverty? *Health Promot Int*. 2020;35(1):93-101.
61. Kibachio J, Mwenda V, Ombiro O, Kamano JH, Perez-Guzman PN, Mutai KK, et al. Recommendations for the use of mathematical modelling to support decision-making on integration of non-communicable diseases into HIV care. *J Int AIDS Soc*. 2020;23 Suppl 1(Suppl 1):e25505.
62. Kibel M, Pierzchalski J, Gorfinkel L, Embleton L, Ayuku D, Hogg R, et al. Standardized mortality ratios between street-connected young people and the general age-equivalent population in an urban setting in Kenya from 2010 to 2015. *Glob Health Action*. 2020;13(1):1802097.
63. Kimani W, Ashiundu E, Saula PW, Kimondo M, Keitany K. Congenital mesoblastic nephroma: Case study. *Journal of Pediatric Surgery Case Reports*. 2020;55:101336.
64. Koskei P, Bii CC, Musotsi P, Muturi Karanja S. Postharvest Storage Practices of Maize in Rift Valley and Lower Eastern Regions of Kenya: A Cross-Sectional Study. *Int J Microbiol*. 2020;2020:6109214.
65. Krown SE, Moser CB, MacPhail P, Matining RM, Godfrey C, Caruso SR, et al. Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. *Lancet*. 2020;395(10231):1195-207.
66. Kuerten BG, Brotkin S, Bonner MJ, Ayuku DO, Njuguna F, Taylor SM, et al. Psychosocial Burden of Childhood Sickle Cell Disease on Caregivers in Kenya. *Journal of pediatric psychology*. 2020;45(5):561-72.
67. Kyololo OM, Stevens BJ, Songok J. Procedural pain in hospitalized neonates in Kenya. *J Pediatr Nurs*. 2020;58:15-20.
68. Laktabai J, Saran I, Zhou Y, Simmons RA, Turner EL, Visser T, et al. Subsidise the test, the treatment or both? Results of an individually randomised controlled trial of the management of suspected malaria fevers in the retail sector in western Kenya. *BMJ Glob Health*. 2020;5(11).
69. Langat S, Njuguna F, Kaspers G, Mostert S. Health insurance coverage for vulnerable children: two HIV orphans with Burkitt lymphoma and their quest for health insurance coverage in Kenya. *BMJ Case Rep*. 2020;13(8).
70. Lanys A, Krikler G, Spitzer RF. The impact of a global health elective on CanMEDS competencies and future practice. *Hum Resour Health*. 2020;18(1):6.
71. Leung CL, Naert M, Andama B, Dong R, Edelman D, Horowitz C, et al. Human-centered design as a guide to intervention planning for non-communicable diseases: the BIGPIC study from Western Kenya. *BMC Health Serv Res*. 2020;20(1):415.
72. Li W, McHenry M, Oyungu E, Yang J, Xia Y, Syed F, et al. Immune checkpoint dysregulation and immune activation in HIV-exposed uninfected children. *Am Assoc Immunol*; 2020.
73. Lin LL, Lakomy DS, Chiao EY, Strother RM, Wirth M, Cesarman E, et al. Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming Barriers. *JCO Glob Oncol*. 2020;6:1134-46.

74. Loiseau C, Brites D, Reinhard M, Zürcher K, Borrell S, Ballif M, et al. HIV Coinfection Is Associated with Low-Fitness rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis. *Antimicrob Agents Chemother*. 2020;64(10).
75. Love KR, Karin E, Morogo D, Toroitich F, Boit JM, Tarus A, et al. "To Speak of Death Is to Invite It": Provider Perceptions of Palliative Care for Cardiovascular Patients in Western Kenya. *J Pain Symptom Manage*. 2020;60(4):717-24.
76. Luhumyo L, Mwaliko E, Tonui P, Getanda A, Hann K. The magnitude of intimate partner violence during pregnancy in Eldoret, Kenya: exigency for policy action. *Health Policy Plan*. 2020;35(Supplement\_1):i7-i18.
77. Lukandu OM, Koskei LC, Dimba EO. Motivations for a Career in Dentistry among Dental Students and Dental Interns in Kenya. *International journal of dentistry*. 2020;2020:1017979.
78. Lumsden R, Barasa F, Park LP, Ochieng CB, Alera JM, Millar HC, et al. High Burden of Cardiac Disease in Pregnancy at a National Referral Hospital in Western Kenya. *Glob Heart*. 2020;15(1):10.
79. Lusambili AM, Naanyu V, Wade TJ, Mossman L, Mantel M, Pell R, et al. Deliver on Your Own: Disrespectful Maternity Care in rural Kenya. *PLoS ONE*. 2020;15(1):e0214836.
80. Ly K, Chang AY, Kiprono SK, Jose M, Smith MP, Beck K, et al. Implementation of an Ultraviolet Phototherapy Service at a National Referral Hospital in Western Kenya: Reflections on Challenges and Lessons Learned. *Dermatol Ther (Heidelb)*. 2020;10(1):107-17.
81. Maffioli EM, Mohanan M, Saran I, O'Meara WP. Does improving appropriate use of malaria medicines change population beliefs in testing and treatment? Evidence from a randomized controlled trial. *Health Policy Plan*. 2020;35(5):556-66.
82. Maldonado LY, Bone J, Scanlon ML, Anusu G, Chelagat S, Jumah A, et al. Improving maternal, newborn and child health outcomes through a community-based women's health education program: a cluster randomised controlled trial in western Kenya. *BMJ Glob Health*. 2020;5(12).
83. Maldonado LY, Songok JJ, Snelgrove JW, Ochieng CB, Chelagat S, Ikemeri JE, et al. Promoting positive maternal, newborn, and child health behaviors through a group-based health education and microfinance program: a prospective matched cohort study in western Kenya. *BMC Pregnancy Childbirth*. 2020;20(1):288.
84. Marete I, Ekhuagere O, Bann CM, Bucher SL, Nyongesa P, Patel AB, et al. Regional trends in birth weight in low- and middle-income countries 2013-2018. *Reprod Health*. 2020;17(Suppl 3):176.
85. Martin AR, Atkinson EG, Chapman SB, Stevenson A, Stroud RE, Abebe T, et al. Low-coverage sequencing cost-effectively detects known and novel variation in underrepresented populations. *bioRxiv*. 2020:2020.04.27.064832.
86. Masibo PK, Humwa F, Macharia TN. The double burden of overnutrition and undernutrition in mother-child dyads in Kenya: demographic and health survey data, 2014. *J Nutr Sci*. 2020;9:e5.
87. Mburu E, Akello W, Kimani W, Saula PW, Kuremu RT. Trans-anal protrusion of intussusception. *Journal of Pediatric Surgery Case Reports*. 2020;55:101405.
88. Mbuthia GW, Nyamogoba HDN, Chiang SS, McGarvey ST. Burden of stigma among tuberculosis patients in a pastoralist community in Kenya: A mixed methods study. *PLoS ONE*. 2020;15(10):e0240457.

89. McClure EM, Garces AL, Hibberd PL, Moore JL, Goudar SS, Saleem S, et al. The Global Network Maternal Newborn Health Registry: a multi-country, community-based registry of pregnancy outcomes. *Reprod Health*. 2020;17(Suppl 2):184.
90. McClure EM, Saleem S, Goudar SS, Garces A, Whitworth R, Esamai F, et al. Stillbirth 2010-2018: a prospective, population-based, multi-country study from the Global Network. *Reprod Health*. 2020;17(Suppl 2):146.
91. McCrary AW, Nyandiko WM, Ellis AM, Chakraborty H, Muehlbauer MJ, Koech MM, et al. Early cardiac dysfunction in children and young adults with perinatally acquired HIV. *Aids*. 2020;34(4):539-48.
92. Mehta N, Orang'o O, Itsura P, Tonui P, Bussmann H, Bogers JP, et al. Loop Electrosurgical Excision Procedure Treats Cervical Intraepithelial Neoplasia 2/3 Among HIV- and HIV+ Women in Kenya. *J Low Genit Tract Dis*. 2020;24(1):21-6.
93. Menon S, Benova L, Mabeya H. Epilepsy management in pregnant HIV+ women in sub-Saharan Africa, clinical aspects to consider: a scoping review. *BMC Med*. 2020;18(1):341.
94. Mercer T, Nulu S, Vedanthan R. Innovative Implementation Strategies for Hypertension Control in Low- and Middle-Income Countries: a Narrative Review. *Curr Hypertens Rep*. 2020;22(5):39.
95. Mezger NCS, Feuchtner J, Griesel M, Hammerl L, Seraphin TP, Zietsman A, et al. Clinical presentation and diagnosis of adult patients with non-Hodgkin lymphoma in Sub-Saharan Africa. *Br J Haematol*. 2020;190(2):209-21.
96. Millar HC, Keter AK, Musick BS, Apondi E, Wachira J, MacDonald KR, et al. Decreasing incidence of pregnancy among HIV-positive adolescents in a large HIV treatment program in western Kenya between 2005 and 2017: a retrospective cohort study. *Reprod Health*. 2020;17(1):191.
97. Mohamed AA, Oduor C, Kinyanjui D. HIV-associated neurocognitive disorders at Moi teaching and referral hospital, Eldoret, Kenya. *BMC Neurol*. 2020;20(1):280.
98. Momanyi K, Dinant GJ, Bouwmans M, Jaarsma S, Chege P. Current status of family medicine in Kenya; family physicians' perception of their role. *Afr J Prim Health Care Fam Med*. 2020;12(1):e1-e4.
99. Momanyi K, Geert-Jan D, Bouwmans M, Jaarsma S, Chege P. Current status of family medicine in Kenya; family physicians' perception of their role. *African Journal of Primary Health Care & Family Medicine*. 2020;12(a2404).
100. Mpofu PB, Bakoyannis G, Yiannoutsos CT, Mwangi AW, Mburu M. A pseudo-likelihood method for estimating misclassification probabilities in competing-risks settings when true-event data are partially observed. *Biom J*. 2020;82(7):1747-68.
101. Mutakha GS, Mwaliko E, Kirwa P. Clinical bleeding patterns and management techniques of abnormal uterine bleeding at a teaching and referral hospital in Western Kenya. *PLoS ONE*. 2020;15(12):e0243166.
102. Mwogi T, Mercer T, Tran DNT, Tonui R, Tylleskar T, Were MC. Therapeutic turnaround times for common laboratory tests in a tertiary hospital in Kenya. *PLoS ONE*. 2020;15(4):e0230858.
103. Naanyu V, Mujumdar V, Ahearn C, McConnell M, Cohen J. Why do women deliver where they had not planned to go? A qualitative study from peri-urban Nairobi Kenya. *BMC Pregnancy Childbirth*. 2020;20(1):30.

104. Naanyu V, Ruff J, Goodrich S, Spira T, Bateganya M, Toroitich-Ruto C, et al. Qualitative exploration of perceived benefits of care and barriers influencing HIV care in trans Nzoia, Kenya. *BMC Health Serv Res.* 2020;20(1):355.
105. Naanyu V, Wade TJ, Ngetich A, Mulama K, Nyaga L, Pell R, et al. A qualitative exploration of barriers to health-facility-based delivery in Bomachoge-Borabu and Kaloleni, Kenya. *Int J Gynaecol Obstet.* 2020.
106. Nabwera HM, Wright JL, Patil M, Dickinson F, Godia P, Maua J, et al. 'Sometimes you are forced to play God...': a qualitative study of healthcare worker experiences of using continuous positive airway pressure in newborn care in Kenya. *BMJ Open.* 2020;10(8):e034668.
107. Nderitu D, Kamaara E. The Aristotelian model of friendship and the IU-Kenya Partnership. *Indian journal of medical ethics.* 2020;V(2):107-16.
108. Nderitu D, Kamaara E. Gambling with COVID-19 Makes More Sense: Ethical and Practical Challenges in COVID-19 Responses in Communalistic Resource-Limited Africa. *J Bioeth Inq.* 2020;17(4):607-11.
109. Ndinya C, Onyango E, Dinssa FF, Odendo M, Simon JE, Weller S, et al. Participatory Variety Selection of Three African Leafy Vegetables in Western Kenya. *Journal of Medicinally Active Plants.* 2020;9(3):145-56.
110. Ngugi PN, Gesicho MB, Babic A, Were MC. Assessment of HIV Data Reporting Performance by Facilities During EMR Systems Implementations in Kenya. *Stud Health Technol Inform.* 2020;272:167-70.
111. Njeru M, Kang'ethe S, Kwena A, Otieno C. Perceptions of the adequacy of teaching and learning resources for undergraduate medicine (MBChB) and nursing (BScN) programmes in two Kenyan public universities. *Central African Journal of Public Health.* 2020;6(3):106-9.
112. Njuguna B, Fletcher SL, Akwanalo C, Asante KP, Baumann A, Brown A, et al. Proactive prevention: Act now to disrupt the impending non-communicable disease crisis in low-burden populations. *PLoS ONE.* 2020;15(12):e0243004.
113. Nordberg B, Gabriel EE, Were E, Kaguiri E, Ekström AM, Kågesten A, et al. Social concerns related to HIV status disclosure and participation in the prevention of mother-to-child transmission of HIV care among pregnant women in Kenya. *BMC Pregnancy Childbirth.* 2020;20(1):225.
114. O'Meara WP, Simmons R, Bullins P, Freedman B, Abel L, Mangeni J, et al. Mosquito Exposure and Malaria Morbidity: A Microlevel Analysis of Household Mosquito Populations and Malaria in a Population-Based Longitudinal Cohort in Western Kenya. *J Infect Dis.* 2020;221(7):1176-84.
115. Ochomo EO, Ndege S, Itsura P. Focused Training of Community Health Volunteers on Cervical Cancer in Rural Kisumu. *Journal of cancer education : the official journal of the American Association for Cancer Education.* 2020.
116. Odondi RN, Shitsinzi R, Emarah A. Clinical patterns and early outcomes of burn injuries in patients admitted at the Moi Teaching and Referral Hospital in Eldoret, Western Kenya. *Heliyon.* 2020;6(3):e03629.
117. Ogola EN, Barasa A, Gachemba YM, Barasa F, Gitura BM, Nalwa W, et al. May Measurement Month 2018: an analysis of blood pressure screening from Kenya. *Eur Heart J Suppl.* 2020;22(Suppl H):H74-h6.



118. Okoyo Opiyo R, Nyawade SA, McCaul M, Nyasulu PS, Lango DB, Were AJO, et al. Perceptions on Adherence to Dietary Prescriptions for Adults with Chronic Kidney Disease on Hemodialysis: A Qualitative Study. *Diseases*. 2020;8(3).
119. Olbara G, Martijn HA, Njuguna F, Langat S, Martin S, Skiles J, et al. Influence of health insurance status on childhood cancer treatment outcomes in Kenya. *Support Care Cancer*. 2020;28(2):917-24.
120. Olender SA, Perez KK, Go AS, Balani B, Price-Haywood EG, Shah NS, et al. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care. *Clin Infect Dis*. 2020.
121. Onyango CG, Ogonda L, Guyah B, Shiluli C, Ganda G, Orang'o OE, et al. Novel biomarkers with promising benefits for diagnosis of cervical neoplasia: a systematic review. *Infectious agents and cancer*. 2020;15(1):68.
122. Opiyo RO, Were A, Nabakwe E, Mbogo A, Olenja JM, Bukania Z. Patients with Chronic Kidney Disease: How Can They Make Informed Nutritional Decisions? Kenya Policy Briefs Towards Relisation of Vision 2030. 2020;1(2).
123. Orang'o EO, Emont JP, Ermel AC, Liu T, Omodi V, Tong Y, et al. Detection of types of HPV among HIV-infected and HIV-uninfected Kenyan women undergoing cryotherapy or loop electrosurgical excision procedure. *Int J Gynaecol Obstet*. 2020;151(2):279-86.
124. Orang'o EO, Were E, Rode O, Muthoka K, Byczkowski M, Sartor H, et al. Novel concepts in cervical cancer screening: a comparison of VIA, HPV DNA test and p16(INK4a)/Ki-67 dual stain cytology in Western Kenya. *Infectious agents and cancer*. 2020;15:57.
125. Orang'o EO, Emont JP, Ermel AC, Liu T, Omodi V, Tong Y, et al. Detection of types of HPV among HIV-infected and HIV-uninfected Kenyan women undergoing cryotherapy or loop electrosurgical excision procedure. *International Journal of Gynecology & Obstetrics*. 2020.
126. Osetinsky B, Mwangi A, Pastakia S, Wilson-Barthes M, Kimetto J, Rono K, et al. Layering and scaling up chronic non-communicable disease care on existing HIV care systems and acute care settings in Kenya: a cost and budget impact analysis. *J Int AIDS Soc*. 2020;23 Suppl 1(Suppl 1):e25496.
127. Ott MA, Apondi E, MacDonald KR, Embleton L, Thorne JG, Wachira J, et al. Peers, Near-Peers, and Outreach Staff to Build Solidarity in Global HIV Research With Adolescents. *Am J Bioeth*. 2020;20(5):72-4.
128. Owuor HO. Comparison of postpartum family planning uptake between primiparous and multiparous women in Webuye County Hospital, Kenya. *S Afr Fam Pract* (2004). 2020;62(1):e1-e5.
129. Owuor OH, Akiruga JA, Laktabai J, Ateya S, Omar SM. Postpartum psychosis in peripartum cardiomyopathy: a case report. *BMC Psychiatry*. 2020;20(1):114.
130. Oyando R, Njoroge M, Nguhiu P, Sigilai A, Kirui F, Mbui J, et al. Patient costs of diabetes mellitus care in public health care facilities in Kenya. *Int J Health Plann Manage*. 2020;35(1):290-308.
131. Palk AC, Bitta M, Kamaara E, Stein DJ, Singh I. Investigating assumptions of vulnerability: A case study of the exclusion of psychiatric inpatients as participants in genetic research in low- and middle-income contexts. *Developing World Bioethics*. 2020;20(3):157-66.
133. Papas RK, Gakinya BN, Mwaniki MM, Lee H, Keter AK, Martino S, et al. A randomized clinical trial of a group cognitive-behavioral therapy to reduce alcohol use among human immunodeficiency virus-infected outpatients in western Kenya. *Addiction*. 2020.

134. Parcesepe AM, Lancaster K, Edelman EJ, DeBoni R, Ross J, Atwoli L, et al. Substance use service availability in HIV treatment programs: Data from the global IeDEA consortium, 2014-2015 and 2017. *PLoS ONE*. 2020;15(8):e0237772.
135. Park SM, Visbal-Onufrak MA, Haque M, Were MC, Naanyu V, Hasan K, et al. mHealth spectroscopy of blood hemoglobin with spectral super-resolution. *Optica*. 2020;7(6):563-73.
137. Pastakia SD, Braitstein P, Galárraga O, Genberg B, Said J, Vedanthan R, et al. Preserving 2 decades of healthcare gains for Africa in the coronavirus disease 2019 era. *Aids*. 2020;34(12):1761-3.
138. Pastakia SD, Tran DN, Manji I, Schellhase E, Karwa R, Miller ML, et al. Framework and case study for establishing impactful global health programs through academia - biopharmaceutical industry partnerships. *Res Social Adm Pharm*. 2020;16(11):1519-25.
139. Patel AB, Bann CM, Garces AL, Krebs NF, Lokangaka A, Tshetu A, et al. Development of the Global Network for Women's and Children's Health Research's socioeconomic status index for use in the network's sites in low and lower middle-income countries. *Reprod Health*. 2020;17(Suppl 3):193.
140. Patel AB, Simmons EM, Rao SR, Moore J, Nolen TL, Goldenberg RL, et al. Evaluating the effect of care around labor and delivery practices on early neonatal mortality in the Global Network's Maternal and Newborn Health Registry. *Reprod Health*. 2020;17(Suppl 2):156.
141. Patel P, Kaiser BN, Meade CS, Giusto A, Ayuku D, Puffer E. Problematic alcohol use among fathers in Kenya: Poverty, people, and practices as barriers and facilitators to help acceptance. *Int J Drug Policy*. 2020;75:102576.
142. Patsis I, Goodrich S, Yiannoutsos CT, Brown SA, Musick BS, Diero L, et al. Lower rates of ART initiation and decreased retention among ART-naïve patients who consume alcohol enrolling in HIV care and treatment programs in Kenya and Uganda. *PLoS ONE*. 2020;15(10):e0240654.
143. Patten G, Puthanakit T, McGowan CC, Wools-Kaloustian K, Hazra R, Pinto JA, et al. Raltegravir use and outcomes among children and adolescents living with HIV in the IeDEA global consortium. *J Int AIDS Soc*. 2020;23(7):e25580.
144. Peprah S, Ogwang MD, Kerchan P, Reynolds SJ, Tenge CN, Were PA, et al. Mean platelet counts are relatively decreased with malaria but relatively increased with endemic Burkitt Lymphoma in Uganda, Tanzania, and Kenya. *Br J Haematol*. 2020;190(5):772-82.
145. Peprah S, Ogwang MD, Kerchan P, Reynolds SJ, Tenge CN, Were PA, et al. Risk factors for Burkitt lymphoma in East African children and minors: A case-control study in malaria-endemic regions in Uganda, Tanzania and Kenya. *Int J Cancer*. 2020;146(4):953-69.
146. Peter IM, Deraney RN, Orango O, Philip T, Rosen B, Cu-Uvin S. Radical hysterectomy for operable early cervical cancer in HIV-positive and HIV-negative women in western Kenya. *Int J Gynaecol Obstet*. 2020;148(3):403-4.
147. Pett SL, Spyer M, Haddow LJ, Nhema R, Benjamin LA, Najjuka G, et al. Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status. *Aids*. 2020.
148. Poli PA, Orang'o EO, Mwangi A, Barasa FA. Factors Related to Maternal Adverse Outcomes in Pregnant Women with Cardiac Disease in Low-resource Settings. *Eur Cardiol*. 2020;15:e68.
149. Puffer ES, Friis Healy E, Green EP, M. Giusto A, N. Kaiser B, Patel P, et al. Family Functioning and Mental Health Changes Following a Family Therapy Intervention in Kenya: a Pilot Trial. *Journal of Child and Family Studies*. 2020.

150. Pusdekar YV, Patel AB, Kurhe KG, Bhargav SR, Thorsten V, Garces A, et al. Rates and risk factors for preterm birth and low birthweight in the global network sites in six low- and low middle-income countries. *Reprod Health*. 2020;17(Suppl 3):187.
151. Rebeiro PF, Duda SN, Wools-Kaloustian KK, Nash D, Althoff KN. Implications of COVID-19 for HIV Research: data sources, indicators and longitudinal analyses. *J Int AIDS Soc*. 2020;23(10):e25627.
152. Redmond LS, Ogwang MD, Kerchan P, Reynolds SJ, Tenge CN, Were PA, et al. Endemic Burkitt lymphoma: a complication of asymptomatic malaria in sub-Saharan Africa based on published literature and primary data from Uganda, Tanzania, and Kenya. *Malar J*. 2020;19(1):239.
153. Reid D, Chelagat D, Gulbas L, Mercer T, Walker L, Zuniga J, et al. Assessment of term newborn care recommendations in the curricula at a baccalaureate-level nursing school and tertiary public maternity hospital in western Kenya: an analysis of secondary data from a rapid, focused, ethnographic assessment. *The Lancet Global Health*. 2020;8:S36.
154. Rialeem F, Gu JP, Naanyu V, Ali Z, Chege P, Chelagat D, et al. Knowledge and Perceptions Regarding Palliative Care Among Religious Leaders in Uasin Gishu County, Kenya: Survey and Focus Group Analysis. *The American journal of hospice & palliative care*. 2020;37(10):779-84.
155. Rosenberg M, Amisi JA, Szkwarko D, Tran DN, Genberg B, Luetke M, et al. The relationship between a microfinance-based healthcare delivery platform, health insurance coverage, health screenings, and disease management in rural Western Kenya. *BMC Health Serv Res*. 2020;20(1):868.
156. Saleem S, Naqvi F, McClure EM, Nowak KJ, Tikmani SS, Garces AL, et al. Neonatal deaths in infants born weighing  $\geq 2500$  g in low and middle-income countries. *Reprod Health*. 2020;17(Suppl 2):158.
157. Saran I, Winn L, Kipkoech Kirui J, Menya D, Prudhomme O'Meara W. The relative importance of material and non-material incentives for community health workers: Evidence from a discrete choice experiment in Western Kenya. *Soc Sci Med*. 2020;246:112726.
158. Seth D, Williams VL, McMahan DE, Regan S, Busakhala N, Wools-Kaloustian K, et al. The role of dermatology in Kaposi sarcoma diagnosis across three regions in sub-Saharan Africa. *J Am Acad Dermatol*. 2020.
159. Shaikh S, Ashraf H, Shaikh K, Iraqi H, Ndour Mbaye M, Kake A, et al. Diabetes Care During Hajj. *Diabetes therapy : research, treatment and education of diabetes and related disorders*. 2020;11(12):2829-44.
160. Shangani S, Genberg B, Harrison A, Pellowski J, Wachira J, Naanyu V, et al. Cultural adaptation and validation of a measure of prejudice against men who have sex with men among healthcare providers in western Kenya. *Global public health*. 2020:1-15.
161. Shukla VV, Eggleston B, Ambalavanan N, McClure EM, Mwenechanya M, Chomba E, et al. Predictive Modeling for Perinatal Mortality in Resource-Limited Settings. *JAMA Netw Open*. 2020;3(11):e2026750.
162. So-Armah K, Benjamin LA, Bloomfield GS, Feinstein MJ, Hsue P, Njuguna B, et al. HIV and cardiovascular disease. *The lancet HIV*. 2020;7(4):e279-e93.
163. Stokes CM, Alonso J, Andrade LH, Atwoli L, Cardoso G, Chiu WT, et al. Pre-marital predictors of marital violence in the WHO World Mental Health (WMH) Surveys. *Social psychiatry and psychiatric epidemiology*. 2020;55(3):393-405.

164. Strother RM, Gopal S, Wirth M, Chadburn A, Noy A, Cesarman E, et al. Challenges of HIV Lymphoma Clinical Trials in Africa: Lessons From the AIDS Malignancy Consortium 068 Study. *JCO Glob Oncol*. 2020;6:1034-40.
165. Sutherland SC, Shannon HS, Ayuku D, Streiner DL, Saarela O, Atwoli L, et al. Reliability and validity of the RS14 in orphaned and separated adolescents and youths in western Kenya. *PLoS ONE*. 2020;15(11):e0241699.
166. Thorne JG, Buitendyk M, Wawuda R, Lewis B, Bernard C, Spitzer RF. The reproductive health fall-out of a global pandemic. *Sex Reprod Health Matters*. 2020;28(1):1763577.
167. Titus M, Ermel A, Moormann A, Cu-Uvin S, Orang'o O, Tonui P, et al. Low sensitivity of the careHPV™ Assay for detection of Oncogenic Human Papillomavirus in cervical samples from HIV-infected and HIV-uninfected Kenyan women. *Int J Clin Virol*. 2020;4:001-5.
168. Tong Y, Tonui P, Ermel A, Orang'o O, Wong N, Titus M, et al. Persistence of oncogenic and non-oncogenic human papillomavirus is associated with human immunodeficiency virus infection in Kenyan women. *SAGE Open Med*. 2020;8:2050312120945138.
169. Torrorey-Sawe R, van der Merwe N, Mining SK, Kotze MJ. Pioneering Informed Consent for Return of Research Results to Breast Cancer Patients Facing Barriers to Implementation of Genomic Medicine: The Kenyan BRCA1/2 Testing Experience Using Whole Exome Sequencing. *Front Genet*. 2020;11:170.
170. Tran DN, Manji I, Njuguna B, Kamano J, Laktabai J, Tonui E, et al. Solving the problem of access to cardiovascular medicines: revolving fund pharmacy models in rural western Kenya. *BMJ Glob Health*. 2020;5(11).
171. Turissini M, Mercer T, Baenziger J, Atwoli L, Einterz R, Gardner A, et al. Developing Ethical and Sustainable Global Health Educational Exchanges for Clinical Trainees: Implementation and Lessons Learned from the 30-Year Academic Model Providing Access to Healthcare (AMPATH) Partnership. *Ann Glob Health*. 2020;86(1):137.
172. Tymejczyk O, Brazier E, Wools-Kaloustian K, Davies MA, Dilorenzo M, Edmonds A, et al. Impact of Universal Antiretroviral Treatment Eligibility on Rapid Treatment Initiation Among Young Adolescents with Human Immunodeficiency Virus in Sub-Saharan Africa. *J Infect Dis*. 2020;222(5):755-64.
173. Umoren RA, Bucher S, Purkayastha S, Ezeaka C, Esamai F, Mairami A, et al. eHBB/mHBS-DHIS2: Mobile Virtual Reality Provider Training in Helping Babies Breathe®. *Pediatrics*. 2020;146(1 MeetingAbstract):290.
174. Umoren RA, Ezeaka C, Esamai F, Kshatriya BA, Avanigadda P, Clopp B, et al. Pre-Training Cognitive and Psychomotor Gaps in Healthcare Worker Neonatal Resuscitation Skills for Helping Babies Breathe – A Report from the eHBB/mHBS Study. *Pediatrics*. 2020;146(1 Meeting Abstract):378.
175. van der Spek L, Sanglier S, Mabeya HM, van den Akker T, Mertens P, Houweling TAJ. Socioeconomic differences in caesarean section - are they explained by medical need? An analysis of patient record data of a large Kenyan hospital. *Int J Equity Health*. 2020;19(1):117.
176. Vedanthan R, Kumar A, Kamano JH, Chang H, Raymond S, Too K, et al. Effect of Nurse-Based Management of Hypertension in Rural Western Kenya. *Glob Heart*. 2020;15(1):77.

177. von Gaudecker JR, Oduor C, Ofner S, Oyungu E, Said J, Buelow J. Pattern and frequency of neurological and neurosurgical care of adult inpatients and outpatients at a tertiary referral hospital in Kenya. *eNeurologicalSci*. 2020;21:100286.
178. Wafula C, Songole R, Kinyanjui D, Ashraf A. Risk Factors for Psychiatric Morbidity and Demographic Characteristics Among Patients with Facial Injury. *Journal of Anxiety & Depression*. 2020;3.
179. Wainaina E, Otieno CA, Kamau J, Nyachio A, Lowther SA. Norovirus infections and knowledge, attitudes and practices in food safety among food handlers in an informal urban settlement, Kenya 2017. *BMC Public Health*. 2020;20(1):474.
180. Walker SM, Cox E, Revill P, Musiime V, Bwakura-Dangarembizi M, Mallewa J, et al. The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa. *J Int AIDS Soc*. 2020;23(3):e25469.
181. Wall JT, Kaiser BN, Friis-Healy EA, Ayuku D, Puffer ES. What about lay counselors' experiences of task-shifting mental health interventions? Example from a family-based intervention in Kenya. *Int J Ment Health Syst*. 2020;14(1):9.
182. Watson LK, Kaiser BN, Giusto AM, Ayuku D, Puffer ES. Validating mental health assessment in Kenya using an innovative gold standard. *Int J Psychol*. 2020;55(3):425-34.
183. Watts MJ, Middleton DRS, Marriott A, Humphrey OS, Hamilton E, McCormack V, et al. Iodine status in western Kenya: a community-based cross-sectional survey of urinary and drinking water iodine concentrations. *Environ Geochem Health*. 2020;42(4):1141-51.
184. Were E, Kaguiri E, Kiplagat J. Perceptions of occurrence of research misconduct and related factors among Kenyan investigators engaged in HIV research. *Account Res*. 2020;27(6):372-89.
185. Were LPO, Hogan JW, Galárraga O, Wamai R. Predictors of Health Insurance Enrollment among HIV Positive Pregnant Women in Kenya: Potential for Adverse Selection and Implications for HIV Treatment and Prevention. *Int J Environ Res Public Health*. 2020;17(8).
186. Were LPO, Were E, Wamai R, Hogan J, Galarraga O. Effects of social health insurance on access and utilization of obstetric health services: results from HIV+ pregnant women in Kenya. *BMC Public Health*. 2020;20(1):87.
187. Were MC, Gong W, Balirwa P, Balugaba BE, Yeung A, Pierce L, et al. Coverage of IMIA-recommended Competencies by Masters in Health Informatics Degree Programs in East Africa. *Int J Med Inform*. 2020;143:104265.
188. Wigle J, Paul S, Birn AE, Gladstone B, Braitstein P. Youth participation in sexual and reproductive health: policy, practice, and progress in Malawi. *Int J Public Health*. 2020.
189. Yarmoshuk AN, Cole DC, Mwangi M, Guantai AN, Zarowsky C. Reciprocity in international interuniversity global health partnerships. *The International Journal of Higher Education Research*. 2020;v79:395-414.

## Appendix C. Study Reports

---

The following study reports provide summaries of active AMPATH research projects at the end of 2020. Study reports were provided by the projects' Principal Investigator(s) or their designee and provide details on study team specific aims, sites, project period, sponsors, project status, and publications. Summaries are organized alphabetically based on the study title.

<b>Study Title</b>	A cluster randomized trial of 'Teach HADITHI' teacher training intervention to reduce classroom HIV-related stigma in Kenya.
<b>Principal Investigator(s)</b>	Rachel Christine Vreeman (Mount Sinai)
<b>Collaborator(s)</b>	Winstone Nyandiko (Moi University), Edith Apondi (MTRH), Juddy Wachira (Moi University), Wanzhu Tu (Indiana University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: Assemble a multimedia teacher training curriculum package, focused on HIV and HIV stigma and adapted for maximum cultural relevance, curricular cohesion, and impact among Kenyan primary and secondary school teachers. Aim 2: Assess the impact of the Teach HADITHI intervention on Kenyan teachers' attitudes, beliefs, and knowledge about HIV and the level of HIV-related stigma among teachers. Aim 3: Examine whether HIV-infected children and adolescents in classrooms with teachers who have received the Teach HADITHI intervention report less perceived, enacted, or internalized stigma compared to those in classrooms with teachers who have not. Aim 4: Examine the impact of HIV stigma training on stigmatizing knowledge, attitudes, and beliefs about COVID-19.
<b>Site(s)</b>	Moi Teaching and Referral Hospital, Uasin Gishu
<b>Project Period</b>	7/1/2018 - 4/30/2021
<b>Sponsor(s)</b>	US National Institutes of Health
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.
<b>Study Title</b>	A longitudinal survey study of the impact of COVID-19 preparedness and response efforts on people living with HIV in East Africa
<b>Principal Investigator(s)</b>	Kara Wools-Kaloustian (Indiana University)

<b>Collaborator(s)</b>	Lameck Diero (Moi University), Constantin Yiannoustos (Indiana University School of Medicine), Aggrey Sameere (College of Health Sciences Makerere University), et al.
<b>Study Type</b>	Longitudinal observational cohort study
<b>Specific Aim(s)</b>	Aim 1: Assess COVID-19 related knowledge, attitudes, and beliefs among a diverse cohort of people living with HIV in East Africa. Aim 2: Describe the impact of COVID-19 on socio-economic well-being, health status, health services utilization, and health behaviors among a diverse cohort of people living with HIV in East Africa.
<b>Site(s)</b>	Bungoma, Busia, Kisumu, Moi Teaching and Referral Hospital, Trans Nzoia, Uasin Gishu
<b>Project Period</b>	6/9/2020 - ongoing
<b>Sponsor(s)</b>	None
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.

<b>Study Title</b>	A Phase 3, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants with PTSD Taken Daily at Bedtime
<b>Principal Investigator(s)</b>	Lukoye Atwoli (Moi University)
<b>Collaborator(s)</b>	Edith Kwobah, Frank Njenga, Linet Onger, Sylvia Kemunto, Gabriel Kigen
<b>Study Type</b>	Double-blind randomized clinical trial.
<b>Specific Aim(s)</b>	Aim 1: To evaluate the efficacy of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) in treatment of PTSD. Aim 2: To evaluate the safety of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) in the treatment of PTSD.
<b>Site(s)</b>	Moi Teaching and Referral Hospital, KEMRI Nairobi
<b>Project Period</b>	7/1/2020 - 6/30/2023
<b>Sponsor(s)</b>	TONIX Pharmaceuticals
<b>Status</b>	Not started -- Study activities have not begun.

<b>Study Title</b>	A prospective cohort among people living with HIV (leDEA-SRN)
--------------------	---

<b>Principal Investigator(s)</b>	Niharika Samala (Indiana University)
<b>Collaborator(s)</b>	Kara Wools-Kaloustian, Lameck Diero, Suzanne Goodrich, Edith Kwobah, Mercy Karoney, Ayub Barasa, Alexa Monroy, Samir Gupta, Fatuma Some
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	To establish a network of research sites, the Sentinel Research Network (SRN), and to capture and analyze standardized data among PLHIV in LMICs. Through this network, we further seek to implement studies on cardiovascular risk factors, mental health, alcohol and other substance use disorders, as well as liver disease prevalence and associated factors among PLHIV accessing care in LMICs.
<b>Site(s)</b>	Moi Teaching and Referral Hospital
<b>Project Period</b>	8/1/2020 - 7/31/2022
<b>Sponsor(s)</b>	NIH
<b>Status</b>	Not started -- Study activities have not begun.

<b>Study Title</b>	A randomized experiment of malaria diagnostic testing and conditional subsidies to target ACTs in the retail sector: the TESTsmART trial AIM 1
<b>Principal Investigator(s)</b>	Jeremiah Laktabai (Moi University)
<b>Collaborator(s)</b>	Diana Menya (Moi University), Wendy O'Meara (Duke University)
<b>Study Type</b>	Randomised controlled trial
<b>Specific Aim(s)</b>	The objective of this experiment is to identify the combination of RDT and conditional (diagnosis-dependent) ACT subsidies that maximize the percent of clients receiving an RDT. We will test two different RDT price levels and two discounted ACT price levels in a factorial design. ACT discounts are conditional on a positive RDT result. The primary outcome measure is the decision to purchase an RDT before purchasing a drug. Secondary outcome measures are: Decision to purchase an ACT stratified by testing status: (a.) Positive mRDT (b.) Negative mRDT (c.) No malaria test. All outcomes will be measured by interviewing the participant after they make their decision about whether to be tested and which medicines to purchase.
<b>Site(s)</b>	Bungoma, Trans Nzoia
<b>Project Period</b>	10/1/2018 - 9/30/2023
<b>Sponsor(s)</b>	National Institute of Allergy and Infectious Diseases (NIAID)



<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.
<b>Study Title</b>	A randomized experiment of malaria diagnostic testing and conditional subsidies to target ACTs in the retail sector: the TESTsmART trial AIM 2
<b>Principal Investigator(s)</b>	Jeremiah Laktabai (Moi University)
<b>Collaborator(s)</b>	Diana Menya (Moi University), Wendy O'Meara (Duke University)
<b>Study Type</b>	Randomised controlled trial
<b>Specific Aim(s)</b>	The objective of this study is to test the effect of provider-directed and patient-directed incentives on improving the management of suspected malaria fevers that receive care in the retail sector. Provider-directed incentives include small payments for taking the time to conduct malaria-RDT testing for participants with malaria-like illness. Patient-directed incentives are inexpensive RDT testing coupled with a conditional ACT discount. Outcomes will be measured by exit interviews on random days each month at each participating outlet. The primary outcome will be the proportion of all ACTs that are sold to individuals with a positive malaria diagnostic test. The major secondary outcome is the proportion of suspected malaria cases that are tested. This outcome will allow us to determine whether the conditional subsidy can drive demand for testing.
<b>Site(s)</b>	Bungoma, Trans Nzoia
<b>Project Period</b>	10/1/2018 - 9/30/2023
<b>Sponsor(s)</b>	National Institute of Allergy and Infectious Diseases (NIAID)
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.
<b>Study Title</b>	A5300B/I2003B/PHOENix Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENix MDR-TB)
<b>Principal Investigator(s)</b>	Abraham Siika (Moi University)
<b>Collaborator(s)</b>	David Lagat (Moi University)
<b>Study Type</b>	Phase III, open-label, multicenter trial with a cluster-randomized superiority design

<b>Specific Aim(s)</b>	Aim 1: To compare the efficacy of 26 weeks of DLM versus 26 weeks of INH for preventing confirmed or probable active TB during 96 weeks of follow-up. Aim 2: To compare the safety (permanently stopping study drug due to treatment-related adverse events) of 26 weeks of DLM versus 26 weeks of INH for the treatment of presumed latent TB infection (LTBI) with MDR-TB.
<b>Site(s)</b>	Bungoma, Busia, Marakwet, Homa Bay, Kakamega, Kericho, Kisumu, Moi Teaching and Referral Hospital, Nakuru, Nandi, Siaya, Trans Nzoia, Uasin Gishu, Vihiga, West Pokot
<b>Project Period</b>	10/21/2020 - ongoing
<b>Sponsor(s)</b>	NIH
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.

<b>Study Title</b>	A5381 Observational Cohort to Assess Therapeutic Efficacy and Emergence of HIV Drug Resistance Following Initiation of Tenofovir-Lamivudine-Dolutegravir (TLD) for First- or Second-Line ART or with Rifampicin-Containing TB Treatment
<b>Principal Investigator(s)</b>	Abraham Siika (Moi University)
<b>Collaborator(s)</b>	Fatuma Some (Moi University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: Among participants still on TLD at 6 months of followup, to estimate the proportion achieving virologic success (HIV-1 RNA $\leq$ 1000 copies/mL) and the proportion with new DTG resistance mutations in each of the following groups: (a) Participants switching from first-line NNRTI-containing therapy with HIV-1 RNA >1000 copies/mL at start of TLD (Group 1a); (b) Participants switching from second-line PI-containing therapy with HIV-1 RNA >1000 copies/mL at start of TLD (Group 2a); (c) Participants switching from first-line NNRTI-containing therapy with HIV-1 RNA $\leq$ 1000 copies/mL at start of TLD (Group 1b); (d) Participants switching from second-line PI-containing therapy with HIV-1 RNA $\leq$ 1000 copies/mL at start of TLD (Group 2b); (e) Participants who are ART-naïve when starting TLD (Group 4). Aim 2: Among participants taking concomitant TLD (including an additional daily dose of DTG 50 mg) and RIF-containing TB treatment (Group 3), to estimate the proportion achieving virologic success (HIV-1 RNA $\leq$ 1000 copies/mL) and the proportion with new DTG resistance mutations at the end of concomitant treatment.
<b>Site(s)</b>	Busia, Marakwet, Homa Bay, Kakamega, Moi Teaching and Referral Hospital, Nandi, Trans Nzoia, Uasin Gishu, West Pokot

<b>Project Period</b>	10/5/2020 - ongoing
<b>Sponsor(s)</b>	NIH
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.
<b>Study Title</b>	Addressing bioethical research gaps in research with young people living with HIV in Kenya
<b>Principal Investigator(s)</b>	Rami Kantor (Brown University)
<b>Collaborator(s)</b>	Winstone Nyandiko (Moi University), Rachel Vreeman (Mount Sinai), Violet Naanyu (Moi University)
<b>Study Type</b>	Cross-Sectional
<b>Specific Aim(s)</b>	Aim 1: Examine ethical issues in longitudinal clinical research with YPLWH in Kenya from the patient, caregiver, and other key informant perspective. Aim 2: Identify and analyze key bioethics guidelines and policies, as well as academic and grey literature relevant to research with YPLWH across key areas: children and YPLWH, people living with HIV, biological sampling and biobanking, and research in resource-limited settings.
<b>Site(s)</b>	Bungoma, Moi Teaching and Referral Hospital, Trans Nzoia, Uasin Gishu
<b>Project Period</b>	8/18/2020 - 5/30/2024
<b>Sponsor(s)</b>	National Institute of Health (NIH)
<b>Status</b>	Not started -- Study activities have not begun.
<b>Study Title</b>	Addressing HIV drug resistance research gaps in a cohort of perinatally infected Kenyan children and adolescents
<b>Principal Investigator(s)</b>	Rami Kantor (Brown University)
<b>Collaborator(s)</b>	Winstone Nyandiko (Moi University), Rachel Vreeman (Mount Sinai), Joseph Hogan (Brown University), Vladamir Novitsky (Miriam Hospital)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: Investigate genotype-phenotype correlations in HIV-1 subtypes A, C and D. Aim 2: Evaluate etiologies for treatment failure in the presence of a

	'susceptible genotype'. Aim 3: Evaluate etiologies for treatment success in the presence of a 'resistant genotype'.
<b>Site(s)</b>	Bungoma, Moi Teaching and Referral Hospital, Trans Nzoia, Uasin Gishu
<b>Project Period</b>	6/27/2021 - 5/31/2024
<b>Sponsor(s)</b>	National Institute of Health
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.

<b>Study Title</b>	APPROACH
<b>Principal Investigator(s)</b>	Hussein Elias (Moi University)
<b>Collaborator(s)</b>	Eric Finkelstein (Duke University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	To understand the perspectives of patients with advanced cancer regarding their quality of life and end of life care.
<b>Site(s)</b>	Moi Teaching and Referral Hospital
<b>Project Period</b>	1/1/2021 - 12/31/2021
<b>Sponsor(s)</b>	Duke Global Health
<b>Status</b>	Not started -- Study activities have not begun.

<b>Study Title</b>	Bridging Income Generation with Group Integrated Care (BIGPIC)
<b>Principal Investigator(s)</b>	Rajesh Vedanthan (New York University)
<b>Collaborator(s)</b>	Jemima Kamano (Moi University School of Medicine), Violet Naanyu (Moi University School of Medicine), Sonak Pastakia (Purdue University), et al.
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: Identify the contextual factors, facilitators, and barriers that may impact integration of group medical visits and microfinance for CVD risk reduction, using a combination of qualitative research methods: 1) baraza (traditional community gathering) form of inquiry; and 2) focus group discussions among individuals with diabetes or at increased risk for diabetes, microfinance group members, and

	rural health workers. Aim 2: Evaluate the effectiveness of group medical visits and microfinance groups for CVD risk reduction among individuals with diabetes or at increased risk for diabetes, by conducting a four-arm cluster randomized trial comparing: 1) usual clinical care; 2) usual clinical care plus microfinance groups only; 3) group medical visits only (no microfinance); and 4) group medical visits integrated into microfinance groups. The primary outcome measure will be one-year change in systolic blood pressure (SBP), and a key secondary outcome will be change in QRISK2 CVD risk score, which has been validated for Black Africans. Aim 3: Evaluate the incremental cost-effectiveness of each intervention arm of the trial, in terms of costs per unit decrease in SBP, per percent change in CVD risk score, and per disability-adjusted life year saved.
<b>Site(s)</b>	Busia, Kisumu, Trans Nzoia, Uasin Gishu
<b>Project Period</b>	4/1/2015 - 1/31/2022
<b>Sponsor(s)</b>	NIH-NHLBI
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.

<b>Study Title</b>	.Chamas for Change: Adapting a community-based peer-support and health education model for pregnant and parenting adolescents in Kenya
<b>Principal Investigator(s)</b>	Julia Songok (Moi University)
<b>Collaborator(s)</b>	Laura J. Ruhl (Indiana University), Lauren Y. Maldonado (USC), Michael Scanlon (Indiana University), Julie Thorne (University of Toronto), Edith Apondi (MTRH), Astrid Christoffersen-Deb (University of British Columbia)
<b>Study Type</b>	Cross-Sectional
<b>Specific Aim(s)</b>	Aim 1: To adapt the Chamas for Change model and curriculum for community-based, peer-support groups to specifically meet the needs of pregnant adolescents, adolescent mothers, and their children. Aim 2: To assess the feasibility and acceptability of an adapted adolescent Chamas for Change program; Aim 3: To assess the impact of participation on maternal, newborn, and child health outcomes, psychosocial outcomes (i.e. mental health, social support), school re-enrollment, and financial stability among adolescent participants; and Aim 4: To develop a case study to inform possible adaptations of the Chamas for Change model for adolescents to a North American context.
<b>Site(s)</b>	Busia, Trans Nzoia, Uasin Gishu

<b>Project Period</b>	11/4/2019 - ongoing
<b>Sponsor(s)</b>	Clinical and Translational Science Institute (CTSI) - Indiana University
<b>Status</b>	Ongoing
<b>Study Title</b>	Chamas for Change: Validating an integrated community-based strategy of peer support in pregnancy and infancy
<b>Principal Investigator(s)</b>	Julia Songok (Moi University)
<b>Collaborator(s)</b>	Laura Ruhl (Indiana University), Astrid Christoffersen-Deb (University of British Columbia)
<b>Study Type</b>	Prospective Randomized Controlled Trial
<b>Specific Aim(s)</b>	Validate Chama cha MamaToto as a scalable and effective population-wide strategy to rapidly and sustainably achieve high coverage of facility delivery, quality antenatal and postnatal care, long-term FP and EBF. The primary target was to demonstrate a 30% decrease in maternal (MMR), perinatal (PNR), and newborn (NMR) mortality rates.
<b>Site(s)</b>	Trans Nzoia
<b>Project Period</b>	11/1/2017 – 12/31/2020
<b>Sponsor(s)</b>	Grand Challenges Canada-Saving Lives at Birth
<b>Status</b>	Complete -- Follow up and data analysis are complete and the study is closed.
<b>Study Title</b>	Clinical Assessment for Retention and Engagement (CARE Study)
<b>Principal Investigator(s)</b>	Leslie Enane (Indiana University)
<b>Collaborator(s)</b>	Edith Apondi (Moi University), Rachel Vreeman (Mount Sinai), Winstone Nyandiko (Moi University)
<b>Study Type</b>	Cross-Sectional
<b>Specific Aim(s)</b>	Aim 1: Refine a conceptual model for adolescent disengagement from HIV care in East Africa. Aim 2: Develop and pilot an instrument to assess adolescent risk for disengagement from HIV care - the Clinical Assessment for Retention and Engagement (CARE). Aim 3: Develop an evidence-based algorithm to support clinical evaluation and intervention for adolescents at risk for disengagement.

<b>Site(s)</b>	Bungoma, Kisumu, Moi Teaching and Referral Hospital, Nandi, Trans Nzoia, Uasin Gishu
<b>Project Period</b>	10/25/2018 - ongoing
<b>Sponsor(s)</b>	NIH
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.

**Study Title** .Comparison of Nutritional status of children aged 5 to 59 months in community based education and service (COBES)-AMPATH and non AMPATH centres post covid-19

**Principal Investigator(s)** Arthur Kwena (Moi University)

**Collaborator(s)** J. Ballidawa (Moi University), K. Taylor (Notre Dame), M. McDowell (Notre Dame), S. Mining (Moi University)

**Study Type** Cross-Sectional

**Specific Aim(s)** To determine the nutritional status of children in selected COBES centres post Covid-19 and compare the nutritional status in AMPATH and non AMPATH centres.

**Site(s)** Bungoma, Busia, Marakwet, Kakamega, Nandi, Trans Nzoia, Uasin Gishu

**Project Period** 1/1/2014 - ongoing

**Sponsor(s)** None

**Status** Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.

**Study Title** .Developing Capacity of Moi Teaching and Referral Hospital / Moi University Institutional Research Ethics Committee (MTRH/MU IREC), Kenya to Prevent and Manage Research Misconduct.

**Principal Investigator(s)** Edwin Were (Moi University)

**Collaborator(s)** Jepchirchir Kiplagat (Moi University)

**Study Type** Cross-Sectional

**Specific Aim(s)** Aim 1: Estimate the prevalence of and explore stakeholder perceptions on research misconduct and how it can best be addressed in Kenya. Aim 2: Explore

	the perceptions on capacity to prevent, detect and manage research misconduct and the perceived critical components of a model framework for managing research misconduct. Aim 3. Develop and pilot test a model framework for detecting and managing research misconduct.
Site(s)	Kisumu, Moi Teaching and Referral Hospital, KNH, Research Ethics Committees in Kenya
Project Period	8/1/2017 - 7/31/2021
Sponsor(s)	NIH
Status	Ongoing -- In addition to data analysis, other project-related activities including trainings, sensitization workshop, and project evaluation and dissemination are planned for this year.

Study Title	EA-leDEA ACE Study
Principal Investigator(s)	Rachel Vreeman (Mount Sinai)
Collaborator(s)	Kara Wools-Kaloustian (Indiana University), Edith Apondi (MTRH), Batya Elul (Columbia University), Rami Kantor (Brown University), Samuel Ayaya (Moi University), Giorgos Bakoyannis (Indiana University), Leslie Enane (Indiana University), Zachary Kwena (FACES -KEMRI)
Study Type	Cross-Sectional
Specific Aim(s)	Aim 1: Describe the engagement status (engaged, LTP with care disengagement, LTP with re-engagement, or LTFU), virologic suppression status (viral suppression or viral non-suppression), and vital status (alive, dead, or LTFU) for PIA. Aim 2: Provide in-depth characterization of the populations of PIA engaged in and disengaged from care, including describing current HIV care-related characteristics (ART regimen, adherence to treatment, experiences of HIV-related stigma, HIV care preferences); virologic outcomes (viral suppression, viral failure, and drug resistance patterns); pregnancy status; and mental and behavioral health characteristics (depression, substance use). Aim 3: Describe virologic, mental and behavioral health outcomes and HIV care preferences by HIV care status (engaged, LTP with care disengagement, LTP with re-engagement, or LTFU). Aim 4: Identify patient-level factors (including clinical characteristics, mental and behavioral characteristics, and HIV care preferences) associated with HIV care status (engaged, LTP with care disengagement, or LTP with re-engagement), viral suppression, and death.
Site(s)	Moi Teaching and Referral Hospital, Trans Nzoia



<b>Project Period</b>	8/1/2018 - ongoing
<b>Sponsor(s)</b>	NIH/NIAID
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.
<b>Study Title</b>	EA-leDEA Main
<b>Principal Investigator(s)</b>	Kara Wools-Kaloustian (Indiana University)
<b>Collaborator(s)</b>	Constantin Yiannoutsos (Indiana University), Lameck Diero (Moi University), Samuel Ayaya (Moi University)
<b>Study Type</b>	Retrospective
<b>Specific Aim(s)</b>	To collaborate with clinical sites to identify and define key variables, harmonize and effectively analyze the data to generate large datasets.
<b>Site(s)</b>	Bungoma, Busia, Kisumu, Moi Teaching and Referral Hospital, Trans Nzoia, Uasin Gishu, West Pokot
<b>Project Period</b>	8/1/2006 - ongoing
<b>Sponsor(s)</b>	NIH
<b>Status</b>	Ongoing-- Data continues to be generated through POC from the AMPATH care clinics; data from EMR from FACES and from sites in Uganda and Tanzania
<b>Study Title</b>	EA-leDEA Networks In Kenya
<b>Principal Investigator(s)</b>	Jennifer Syvertsen (University of California, Riverside, USA)
<b>Collaborator(s)</b>	Lukoye Atwoli (Moi University), Edith Kwobah (MTRH), Suzanne Goodrich (Indiana University), Karla D Wagner (University of Nevada), Maurice Aluda (KEMRI/FACES), Jayne Kulzer (UCSF), Kara Wools-Kaloustian (Indiana University)
<b>Study Type</b>	Cross-Sectional
<b>Specific Aim(s)</b>	Aim 1: To examine how social network factors (e.g., network size, structure, composition) are associated with patterns of alcohol and other drug use (AOD), sexual behaviors, engagement in care, and HIV clinical outcomes among a sample of EA leDEA-affiliated clinic patients who screen positive for alcohol and/or drug use and a comparison group. Aim 2: To qualitatively describe the

	nature and overlap of key relationships (e.g., risky and supportive) within patients' networks and assess their associations with HIV outcomes. Aim 3: To use mixed methods to explore the feasibility and acceptability of developing a social network intervention to reduce AOD risk behaviors, improve HIV clinical outcomes, and increase linkages to testing and care among people who use alcohol and/or drugs in East Africa.
Site(s)	Moi Teaching and Referral Hospital
Project Period	10/29/2019 - ongoing
Sponsor(s)	NIH
Status	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.

Study Title	EA-leDEA NIDA Study
Principal Investigator(s)	Kara Wools-Kaloustian (Indiana University)
Collaborator(s)	Lameck Diero (Moi University), Suzanne Goodrich (Indiana University), Edith Kwobah (MTRH), Patrick Oyaró (FACES/RCTP/KEMRI), Maurice Aluda (FACES/RCTP/KEMRI), Jayne Kulzer (UCSF)
Study Type	Prospective
Specific Aim(s)	Aim 1: Estimate the prevalence of hazardous alcohol consumption in patients enrolling in HIV- care and compare their baseline characteristic with those of non-drinkers. Aim 2: Compare clinician and research assistant collected AUDIT screening data at one clinic within the East African leDEA consortium. Aim 3: Assess the impact of hazardous drinking on patient outcomes including time to antiretroviral therapy (ART) initiation, medication adherence, retention in care, and death at 6 months and again at 24-36 months. Aim 4: Assess strategies utilized by patients to address their hazardous alcohol use.
Site(s)	Moi Teaching and Referral Hospital
Project Period	7/31/2017 - ongoing
Sponsor(s)	NIH
Status	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.

<b>Study Title</b>	EA-leDEA - PHQ 9 Study
<b>Principal Investigator(s)</b>	Marcel Yotebieng (Albert Einstein College of Medicine)
<b>Collaborator(s)</b>	Kathryn Lancaster (Ohio State University); Lukoye Atwoli (Moi University); Jennifer Syvertsen (University of California, Riverside), Kara Wools-Kaloustian (Indiana University), et al.
<b>Study Type</b>	Cross-Sectional
<b>Specific Aim(s)</b>	Aim 1: Determine the region-specific differences in the quality of measurement afforded by the PHQ-9. Aim 2: Determine the dimensionality of PHQ-9 and assess whether a different scoring system or cut-point is needed among PLWH. Aim 3: Describe how PLWH in both region express mental distress and determine whether reformulation/adaptation of questions in PHQ-9 will improve its performance
<b>Site(s)</b>	Moi Teaching and Referral Hospital
<b>Project Period</b>	11/23/2020 - ongoing
<b>Sponsor(s)</b>	NIH
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.

<b>Study Title</b>	EA-leDEA Syndemics
<b>Principal Investigator(s)</b>	Kara Wools-Kaloustian (Indiana University)
<b>Collaborator(s)</b>	Suzanne Goodrich (Indiana University), Jennifer Syvertsen (University of California Riverside), Jayne Kulzer (UCSF), Maurice Aluda (FACES/RCTP/KEMRI), Lukoye Atwoli (Moi University), Edith Kwobah (MTRH)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: Identify community and clinic-based services available for treatment of substance use and mental health disorders in the three research sites. Aim 2: Determine the prevalence of substance use (drug and alcohol) and mental health disorders in patients enrolling into care. Aim 3: Assess the impact of substance use, mental health disorders and dual diagnoses on patient adherence and retention in the cascade. Aim 4: Conduct qualitative interviews with a sub-

	sample of cohort patients to explore access, use, and experiences with substance use and mental health services.
<b>Site(s)</b>	Moi Teaching and Referral Hospital
<b>Project Period</b>	12/17/2018 - ongoing
<b>Sponsor(s)</b>	NIH
<b>Status</b>	Ongoing -- Follow Up Continues. Enrollment has finished but participants are still receiving research-related intervention, interaction, or follow up.

<b>Study Title</b>	.Enhancing Preventive Therapy of Malaria in children with Sickle Cell Anemia (SCA) in East Africa (EPiTOMISE)
<b>Principal Investigator(s)</b>	Festus Njuguna (Moi University)
<b>Collaborator(s)</b>	Steve Taylor (Duke University), Wendy O'Meara (Duke University)
<b>Study Type</b>	Randomized, three-arm, open-label, clinical trial
<b>Specific Aim(s)</b>	Aim 1: Compare the efficacy of daily Proguanil with that of monthly sulfadoxine/pyrimethamine-amodiaquine (SP-AQ) or monthly dihydroartemisinin-piperaquine (DP) to prevent P. falciparum malaria in children with sickle cell. Aim 2: Compare the efficacy of daily Proguanil, monthly SP-AQ, and monthly DP to prevent painful events in children with sickle cell anemia. Aim 3: Compare the impact of malaria chemoprophylaxis regimens on molecular markers of parasite drug resistance to Proguanil, SP-AQ, and DP.
<b>Site(s)</b>	Homa Bay
<b>Project Period</b>	6/1/2016 - 2/28/2021
<b>Sponsor(s)</b>	The U.S. National Institutes of Health/ National Heart, Lung and Blood Institute (NIH/NHLBI)
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.

<b>Study Title</b>	.Ethnic Specific Risk Stratification in Early Pregnancy for Identifying Mothers at Risk of Gestational Diabetes Mellitus in Eldoret Kenya
<b>Principal Investigator(s)</b>	Wycliffe Kosgei (Moi Teaching and Referral Hospital)

<b>Collaborator(s)</b>	Astrid Christoffersen (University of Toronto), Sonak Pastakia (Purdue University), Wycliffe Kosgei (MTRH)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: To determine the prevalence rates of GDM in rural and urban populations. Aim 2: To assess the impact of the risk factors of interest (age, BMI and family history) for GDM in early pregnancy. Aim 3: To develop and validate of composite risk score for GDM with the risk factors of interest and/or point-of-care HbA1c.
<b>Site(s)</b>	Moi Teaching and Referral Hospital, Uasin Gishu
<b>Project Period</b>	6/13/2016 - ongoing
<b>Sponsor(s)</b>	Medical Reserach Counsel-Warwick University
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.

<b>Study Title</b>	Evaluating reproductive and HIV outcomes and decision-making among HIV-positive women on dolutegravir: A prospective, observational cohort at AMPATH, Kenya
<b>Principal Investigator(s)</b>	John Humphrey (Indiana University)
<b>Collaborator(s)</b>	Rena Patel, Mercy Maina, Julie Thorne, Beatrice Jakait, Caitlin Bernard
<b>Study Type</b>	Retrospective analysis of AMRS data and telephone surveys
<b>Specific Aim(s)</b>	Aim 1. To evaluate key reproductive health and HIV outcomes among women initially on DTG-containing ART. Aim 2: To investigate factors facilitating provider and patient decision-making for HIV-infected women choosing between ART and contraceptive choices.
<b>Site(s)</b>	
<b>Project Period</b>	7/9/2020 - ongoing
<b>Sponsor(s)</b>	NIH and Indiana University
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.

<b>Study Title</b>	Evaluation of Chronic Hypoxemia from Cardiopulmonary Disease Among Patients Admitted to a Referral Hospital in Western Kenya and Their Perspectives on Oxygen Use
<b>Principal Investigator(s)</b>	Neelima Navuluri (Duke University)
<b>Collaborator(s)</b>	David Lagat (Moi University), Peter Kussin (Duke University), Lameck Diero (Moi University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: Determine the prevalence of chronic hypoxemia from cardiopulmonary disease and the associated in-hospital mortality rate among patients admitted to Moi Teaching and Referral Hospital (MTRH) inpatient medicine wards from August 2019 - June 2021. Aim 2: Characterize patients with chronic hypoxemia admitted to MTRH by determining demographic and environmental risk factors, associated co-morbidities such as HIV, and underlying etiologies. Aim 3: Assess quality of life measures among patients with chronic hypoxemia and their perspectives on oxygen therapy.
<b>Site(s)</b>	Moi Teaching and Referral Hospital, Uasin Gishu
<b>Project Period</b>	9/1/2019 - ongoing
<b>Sponsor(s)</b>	NIH-Fogarty
<b>Status</b>	Ongoing -- Follow Up Continues. Enrollment has finished but participants are still receiving research-related intervention, interaction, or follow up.

<b>Study Title</b>	Feasibility and acceptability of Enhanced Patient Care (EPC) for adult HIV patients with unsuppressed viral loads in western Kenya
<b>Principal Investigator(s)</b>	Juddy Wachira (Moi University)
<b>Collaborator(s)</b>	Becky Lynn Genberg (John Hopkins University), Ira Wilson (Brown University), Abraham M. Siika (Moi University), Omar Galarraga (Brown University), Paula Braitstein (University of Toronto) Ann Mwangi (Moi University), Sylvester Kimaiyo (Moi University), Jonathan Dick (Indiana University), Michael Bart Laws (Brown University)
<b>Study Type</b>	Randomized Controlled Trial
<b>Specific Aim(s)</b>	Aim 1. Determine the impact of system-level factors on patient engagement (clinic adherence) among adult HIV patients. Aim 2. Assess the feasibility and acceptability of enhanced patient care (EPC) clinics for promoting patient engagement (clinic adherence) among patients with unsuppressed viral load

	(≥400). Aim 3. Determine the cost effectiveness of EPC for engagement of patients with unsuppressed viral load.
Site(s)	Busia
Project Period	7/3/2017 - 12/30/2022
Sponsor(s)	NIH
Status	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.



Study Title	.Harambee: Integrated Community-Based HIV/NCD Care & Microfinance Groups in Kenya
Principal Investigator(s)	Omar Galárraga (Brown University)
Collaborator(s)	Becky Lynn Genberg (Johns Hopkins University), Juddy Wachira (Moi University)
Study Type	Prospective
Specific Aim(s)	Aim 1: To evaluate the extent to which integrated community-based HIV care with group microfinance affects retention in care and viral suppression among PLHIV in rural western Kenya using a pragmatic cluster randomized intervention design of 40 existing (majority HIV+) microfinance groups to receive microfinance plus either: (A) integrated community-based HIV care, or (B) standard care. Aim 2: To identify specific mechanisms through which microfinance and integrated community-based care impact viral suppression. Aim 3: To assess the cost-effectiveness of microfinance and integrated community-based care delivery to maximize future policy and practice relevance of this promising intervention strategy.
Site(s)	Busia, Trans Nzoia
Project Period	7/5/2019 - 4/30/2024
Sponsor(s)	NIH-NIMH
Status	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.



Study Title	HIV-related outcomes at the AMPATH Drug Resistance Clinic in Kenya
-------------	--

<b>Principal Investigator(s)</b>	John Humphrey (Indiana University)
<b>Collaborator(s)</b>	Shamim Ali, Bilal Syed, Suzanne Goodrich, Celia Ngetch, Beatrice Jakait, Rami Kantor, Adrian Gardner
<b>Study Type</b>	Retrospective
<b>Specific Aim(s)</b>	Aim 1: Describe the clinical characteristics of patients attending the AMPATH HIV Drug Resistance Clinic, including the prevalence of drug resistance mutations. Aim 2: Describe the virologic and ART outcomes of patients failing second and third-line ART, including the proportion of patients who achieve viral suppression following enrollment in the clinic and the proportion experiencing an ART regimen change.
<b>Site(s)</b>	Uasin Gishu
<b>Project Period</b>	3/3/2020 - ongoing
<b>Sponsor(s)</b>	None
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.

<b>Study Title</b>	.Impact of COVID-19 on adolescents living with HIV in Kenya
<b>Principal Investigator(s)</b>	Rami Kantor (Brown University)
<b>Collaborator(s)</b>	Winstone Nyandiko (Moi University), Rachel Vreeman (Mount Sinai)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: Investigate changes in ART adherence, mental health and socio-economic well-being related to COVID-19, and their association with viral failure and DR outcomes in Kenyan ALWH. Aim 2: Estimate exposure to COVID-19 and association with viral failure and DR outcomes among Kenyan ALWH enrolled in the parent grant.
<b>Site(s)</b>	Bungoma, Moi Teaching and Referral Hospital, Trans Nzoia, Uasin Gishu
<b>Project Period</b>	8/20/2020 - 5/31/2024
<b>Sponsor(s)</b>	NIH
<b>Status</b>	Not started -- Study activities have not begun.



<b>Study Title</b>	Implementing a Model of Improved Care for Infectious Diseases and Antibiotic Stewardship across Multiple Levels of the Health System in Western Kenya
<b>Principal Investigator(s)</b>	Charles Kwobah (Moi University)
<b>Collaborator(s)</b>	Shamim Ali (Moi University), Suzanne Goodrich (Indiana University), Adrian Gardner (Indiana University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	To optimize appropriate antibiotic use in order to improve clinical outcomes while minimizing unintentional consequences of use, including the emergence of antimicrobial resistance.
<b>Site(s)</b>	Bungoma, Marakwet, Moi Teaching and Referral Hospital
<b>Project Period</b>	10/1/2019 - 9/30/2022
<b>Sponsor(s)</b>	Pfizer Foundation
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.

<b>Study Title</b>	Improving Estimates of Mother-to-Child Transmission in Western Kenya: A Mixed Methods Prospective Cohort Study - Plus (leDEA PMTCT Plus study)
<b>Principal Investigator(s)</b>	John Humphrey (Indiana University)
<b>Collaborator(s)</b>	John Humphrey, Bett Kipchumba, Marsha Alera, Libby Pfeiffer, Julia Songok, Winfred Mwangi, Wycliffe Kosgei, Beverly Musick, Constantin Yiannoutsos, Juddy Wachira, Kara Wools Kaloustian
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1. Determine the barriers and enhancers to retention in care and viral suppression for postpartum women. Sub-Aim 1a: identify factors influencing retention and viral suppression using (i) statistical methods for observational data that incorporate LTFU outcomes, and (ii) qualitative interviews among 30 postpartum women and 15 of their male partners; Sub-Aim 1b: determine the prevalence of HIV resistance and its association with viral non-suppression by genotyping postpartum blood samples with detectable viremia and stored samples collected during pregnancy and earlier postpartum.
<b>Site(s)</b>	Busia, Trans Nzoia, Uasin Gishu

<b>Project Period</b>	2/1/2021 - 2/1/2022
<b>Sponsor(s)</b>	Internal
<b>Status</b>	Not started -- Study activities have not begun.
<b>Study Title</b>	.Making Inroads to Strengthen the Health of Adolescents
<b>Principal Investigator(s)</b>	Leslie Enane (Indiana University)
<b>Collaborator(s)</b>	Edith Apondi (Moi University), Rachel Vreeman (Mount Sinai), Winstone Nyandiko (Moi University), Elizabeth Lowenthal (University of Pennsylvania)
<b>Study Type</b>	Cross-Sectional
<b>Specific Aim(s)</b>	Aim 1. To quantify missed opportunities along the HIV care cascade among adolescents prior to hospitalization in western Kenya, by examining timing and outcomes of HIV diagnosis, linkage to and retention in care, and viral suppression. (Secondary Aim: To determine the causes of hospitalization and mortality among adolescents with HIV in western Kenya) Aim 2. To define critical barriers contributing to delays or failures in the care cascade, as well as facilitators to care, and to identify areas of potential intervention.
<b>Site(s)</b>	Moi Teaching and Referral Hospital, Uasin Gishu
<b>Project Period</b>	4/12/2017 - ongoing
<b>Sponsor(s)</b>	Indiana University
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.
<b>Study Title</b>	.Maternal Newborn Health Registry
<b>Principal Investigator(s)</b>	Fabian Esamai (Moi University)
<b>Collaborator(s)</b>	Sherri Bucher (Indiana University), Edward Liechty (Indiana University), Irene Marete (Moi University), Constance Tenge (Moi University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	A multicenter (8 sites in 7 countries) prospective, population-based registry which enrolls women during pregnancy and tracks pregnancy, delivery, and

	postnatal maternal and neonatal outcomes through 42 days postpartum. A vital registry system allows the Global Network to document maternal and neonatal mortality, design trials to address the major causes of poor outcomes, assess the outcome of our interventions, and ultimately, disseminate the results as the basis of public health policy.
Site(s)	Bungoma, Busia, Kakamega
Project Period	10/15/2008 - ongoing
Sponsor(s)	NIH - NICHD
Status	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.



Study Title	.Measuring adverse pregnancy and newborn outcomes (MANGO); An leDEA collaboration study
Principal Investigator(s)	Edwin Were (Moi University)
Collaborator(s)	Rena Patel, Julia Songok, Bett Kipchumba, Audry Chepkemboi, Wycliffe Kosgei, Joy Marsha, Catlin Bernard, Beverly Musick, Laura Oyiengo, Elvis Oyungi, Molly MacPheron, Meghan McHenry, Edward Leichty, Ushma Mehta, Emma Kalk, Amy Slogrove, Andrew Boule, Mary-Ann Davieis, Constantine Yiannoultos, Kara Wools-Kaloustian
Study Type	Mixed prospective and retrospective cohort study
Specific Aim(s)	1. Determine event rates for adverse pregnancy outcomes, congenital abnormalities (CAs) and other abnormal conditions in infants born to HIV+ and HIV- women and determine the associations between adverse pregnancy and infant outcomes and ART exposures during conception and pregnancy 2. To create standardized protocols and data exchange standards within IU and leDEA. - By leveraging the existing and extensive leDEA Data Exchange Standard (DES) and creating a Data Standards Task Force and a Data Coordinating Center for PV, we will add new tables and expand existing ones, as necessary, to include new concepts and fields responsive to the needs of pharmacovigilance among pregnant women.
Site(s)	Uasin Gishu
Project Period	8/3/2020 - 7/31/2025
Sponsor(s)	NIH-NICHD

<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.
<b>Study Title</b>	.Mobile Mental Health Monitoring and Support for Adolescents with HIV in Kenya
<b>Principal Investigator(s)</b>	Rachel Vreeman (Mount Sinai)
<b>Collaborator(s)</b>	Winstone Nyandiko (Moi University), Edith Apondi (MTRH), Bree Weaver (Indiana University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: Assess the feasibility, acceptability, and usability of a cell phone-based intervention to provide mental health services (tele-therapy and tele-peer support) for HIV-infected adolescents in Kenya. Aim 2: Evaluate the user engagement with both the cell phone-based intervention and the clinical care system throughout the monitoring period using counselor reports, usage tracking, and clinical database evaluation. Aim 3: Describe key clinical, mental, and emotional health outcomes for this cohort during the monitoring period, including medication and clinic adherence, viral suppression, depression symptoms and other behavioral or emotional symptom reports, and engagement with support services such as peer support groups.
<b>Site(s)</b>	Uasin Gishu
<b>Project Period</b>	1/1/2017 - 12/31/2018
<b>Sponsor(s)</b>	NIMH
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.



<b>Study Title</b>	.Neoinnovate Collaborative Consortium
<b>Principal Investigator(s)</b>	Sherri Bucher (Indiana University)
<b>Collaborator(s)</b>	Saptarshi Purkyastha (Indiana University), Fabian Esamai (Moi University)
<b>Study Type</b>	n/a
<b>Specific Aim(s)</b>	The Neoinnovate Collaborative Consortium is a multi-disciplinary international coalition of faculty, students, and post-graduate trainees led by IU School of Medicine and Alupe University College (Moi University) and partnering with Moi

	Teaching and Referral Hospital (Kenya), IUPUI, Purdue University, and University of Notre Dame. The Consortium builds, deploys, and evaluates innovative solutions by which to equip, empower, and strengthen health care providers, communities, and health systems. These efforts supply partners and stakeholders with the knowledge, skills, and tools by which to successfully disseminate, implement, scale-up, and sustain evidence-based, life-saving interventions to improve maternal and newborn outcomes.
Site(s)	-
Project Period	-
Sponsor(s)	None
Status	n/a

Study Title	.Neurodevelopmental Screening in Children Born to HIV-Infected Mothers in Kenya
Principal Investigator(s)	Megan McHenry (Indiana University)
Collaborator(s)	Eren Oyungu (Moi University)
Study Type	Prospective
Specific Aim(s)	AIM 1: Determine and compare the reliability and validity of neurodevelopmental screening tools and assessments for use among children aged 18-36 months in Kenya. The objective for this aim is to identify an optimal screening tool and assessment for use in Kenya. AIM 2: Evaluate neurodevelopmental screening implementation in an existing healthcare system in Kenya. •Sub-aim 2a: Develop a contextualized implementation plan and Sub-aim 2b: Pilot a ND screening program at one MCH clinic in Kenya. In addition, we will assess effectiveness of ND screening, as determined by sensitivity; specificity; and positive and negative predictive values.
Site(s)	Uasin Gishu
Project Period	9/30/2018 - 8/31/2022
Sponsor(s)	NIH-NIMH
Status	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.

Study Title	.NEUROPSYCHIATRIC GENETICS OF AFRICAN POPULATIONS - PSYCHOSIS (NEUROGAP-P)
-------------	--

<b>Principal Investigator(s)</b>	Lukoye Atwoli (Moi University)
<b>Collaborator(s)</b>	Gabriel Kigen, Edith Kwobah, Wilfred Emonyi
<b>Study Type</b>	Cross-Sectional
<b>Specific Aim(s)</b>	Aim 1: To determine the phenotypic presentation of psychotic disorders in African populations. Aim 2: To describe the genetic variation between patients with psychotic disorders and those without in African populations. Aim 3: To examine the association between genetic variation and risk for schizophrenia and bipolar disorder in African populations. Aim 4: To provide opportunities for training of African scientists in neuropsychiatric genetics research
<b>Site(s)</b>	Bungoma, Marakwet, Kakamega, Moi Teaching and Referral Hospital, Nandi, Trans Nzoia, West Pokot
<b>Project Period</b>	7/1/2017 - 6/30/2021
<b>Sponsor(s)</b>	Broad Institute of MIT & Harvard
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.

<b>Study Title</b>	Optimizing HIV treatment monitoring strategies under resource constraints
<b>Principal Investigator(s)</b>	Rami Kantor (Brown University)
<b>Collaborator(s)</b>	Ann Mwangi (Moi University), Lameck Diero (Moi University), Joseph Hogan (Brown University)
<b>Study Type</b>	The research will use previously collected data and blood samples stored from previously IREC approved AMPATH studies.
<b>Specific Aim(s)</b>	1) Develop and apply scalable statistical framework for optimal targeting of gold standard diagnostic tests used to monitor HIV treatment under resource constraints; 2) Apply causal inference techniques to calibrate decision rules using estimated decision utilities; 3) Develop methods to optimize pooling strategies for viral load testing in resource limited settings; 4) Establish and implement pooling protocols using extant samples from AMPATH patients
<b>Site(s)</b>	Samples stored at The Miriam Hospital, USA
<b>Project Period</b>	2/3/2016 - ongoing
<b>Sponsor(s)</b>	NIH

<b>Status</b>	Data cleaning stage
<b>Study Title</b>	Optimizing Linkage and Retention to Hypertension Care in Rural Kenya (LARK)
<b>Principal Investigator(s)</b>	Valentin Fuster (Mount Sinai)
<b>Collaborator(s)</b>	Jemima Kamano (Moi University), Violet Naanyu (Moi University), Diana Menya (Moi University), Sylvester Kimaiyo (Moi University), Rajesh Vedanthan (NYU Grossman School of Medicine), et al.
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	The objective of this project is to utilize a multi-disciplinary implementation research approach to address the challenge of linking and retaining hypertensive individuals to a hypertension management program. Aim 1: Identify the facilitators and barriers to linking and retaining individuals with high blood pressure to a hypertension care delivery program, using a combination of qualitative research methods. Aim 2: Evaluate the effectiveness of CHWs equipped with a tailored behavioral communication strategy and a smartphone-based tool in improving linkage and reducing blood pressure among hypertensive patients, by conducting a cluster randomized trial comparing: 1) usual care (CHWs with standard training on recruitment of individuals with any chronic condition); 2) CHWs with an additional tailored behavioral communication strategy; and 3) CHWs with a tailored behavioral communication strategy an also equipped with smartphone-based tool linked to the AMRS. Aim 3: Evaluate the incremental cost-effectiveness of each intervention arm of the cluster randomized trial.
<b>Site(s)</b>	Nandi, Uasin Gishu
<b>Project Period</b>	4/1/2012 - 3/31/2022
<b>Sponsor(s)</b>	NHLBI, NYU Grossman School of Medicine
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.
<b>Study Title</b>	.Patient-Centered Disclosure Intervention for HIV-Infected Children, Helping AMPATH Disclose Information and Talk about HIV Infection (HADITHI)
<b>Principal Investigator(s)</b>	Rachel Vreeman (Mount Sinai)

<b>Collaborator(s)</b>	Winstone Nyandiko (Moi University),
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: Expand and modify an existing pediatric HIV disclosure intervention used in Kenya to include patient-centered components. Aim 2: Perform a randomized trial to compare the impact of clinic implementation of the culturally adapted, pediatric disclosure intervention on the prevalence of disclosure and on the medical, psychological and social outcomes for HIV-infected Kenyan children ages 10-15 years compared to children exposed to standard clinical care.
<b>Site(s)</b>	Bungoma, Busia, Kisumu, Moi Teaching and Referral Hospital, Nandi, Trans Nzoia, Uasin Gishu
<b>Project Period</b>	1/9/2012 - 1/9/2016
<b>Sponsor(s)</b>	NIMH
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.

<b>Study Title</b>	.Prevalence and Impact of SARS-CoV-2 Among Pregnant Women in Low- and Middle-income Countries
<b>Principal Investigator(s)</b>	Fabian Esamai (Moi University)
<b>Collaborator(s)</b>	Edward Liechty, Sherri Bucher (Indiana University), Irene Marete (Moi University), Constance Tenge (Moi University), Osayame Ekhaguere (Indiana University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: To determine the prevalence of COVID-19 antibodies in pregnant/recently delivered women in 8 Global Network sites using antibody testing. Aim 2: To compare the maternal, fetal, and neonatal outcomes of COVID-19 antibody positive women vs. antibody negative women including low-birthweight, preterm birth, fetal growth restriction, stillbirth, and neonatal mortality. Aim 3: To assess knowledge, attitudes and practices of pregnant women related to COVID-19 and its prevention during pregnancy.
<b>Site(s)</b>	Bungoma, Busia, Kakamega
<b>Project Period</b>	11/15/2020 - ongoing
<b>Sponsor(s)</b>	NIH (NICHD)



<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.
<b>Study Title</b>	.Prevalence of hypertension among postpartum women with preeclampsia (PET) in Kenya: a prospective cohort study
<b>Principal Investigator(s)</b>	Gerald Bloomfield (Duke University)
<b>Collaborator(s)</b>	Felix Barasa (MTRH), Rebecca Lumsden (Duke University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim1: To determine the prevalence of hypertension at 6 months postpartum among Kenyan mothers with preeclampsia. Sub-aim 1.1: To define the BP trajectory during the postpartum period among Kenyan mothers with preeclampsia. Aim 2: To identify risk factors associated with persistent hypertension among Kenyan mothers with preeclampsia. Aim 3: To characterize the acute cardiac structural and functional abnormalities among Kenyan mothers with preeclampsia. Aim 4: To explore post-delivery follow-up care for women with PET, including knowledge, location, barriers and rates of follow up
<b>Site(s)</b>	Moi Teaching and Referral Hospital
<b>Project Period</b>	1/6/2020 - ongoing
<b>Sponsor(s)</b>	NIH-FIC
<b>Status</b>	Ongoing -- Follow Up Continues. Enrollment has finished but participants are still receiving research-related intervention, interaction, or follow up.
<b>Study Title</b>	.Prevention of maternal and neonatal death/infections with a single oral dose of Azithromycin in women in labor (in low- and middle-income countries): a Randomized Controlled Trial (The A-PLUS study)
<b>Principal Investigator(s)</b>	Alan Tita (University of Alabama at Birmingham)
<b>Collaborator(s)</b>	Fabian Esamai (Moi University), Paul Nyongesa (Moi University), Ed Liechty (Indiana University), Sherri Bucher (Indiana University), Osayame Ekhaguere (Indiana University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: To test the effectiveness of a single dose of prophylactic intrapartum azithromycin compared to placebo in reducing the risk of the composite outcome of maternal death or sepsis. Aim 2: To separately test the effectiveness

	of a single oral dose of intrapartum azithromycin prophylaxis (2 g) compared to placebo in reducing the risk of the composite outcome of intrapartum/neonatal death or sepsis.
<b>Site(s)</b>	Bungoma, Busia, Kakamega
<b>Project Period</b>	10/30/2019 - ongoing
<b>Sponsor(s)</b>	NIH
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.

<b>Study Title</b>	.Prevention of maternal and neonatal death/infections with a single oral dose of Azithromycin in women in labor (in low- and middle-income countries): a Randomized Controlled Trial (The A-PLUS study).
<b>Principal Investigator(s)</b>	Fabian Esamai (Moi University)
<b>Collaborator(s)</b>	Paul Nyongesa (Moi University), Edward Liechty (Indiana University), Sheri Bucher (Indiana University)
<b>Study Type</b>	Randomised clinical trial
<b>Specific Aim(s)</b>	To study the effect of use of Azithromycin during labour on maternal and neonatal infection postpartum
<b>Site(s)</b>	Bungoma, Busia, Kakamega
<b>Project Period</b>	9/1/2020 - 9/30/2023
<b>Sponsor(s)</b>	NICHHD
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.

<b>Study Title</b>	.Prospective study of Lopinavir based ART for HIV Infected children Globally (LIVING study) 2
<b>Principal Investigator(s)</b>	Winstone Nyandiko (Moi University)
<b>Collaborator(s)</b>	Dalton Wamalwa (University of Nairobi), Samwel Ayaya (Moi University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Primary objective: Evaluate the effectiveness of LPV/r pellets in addition to AZT/3TC (or ABC/3TC) paediatric fixed dose combination (FDCs) tablet under

	<p>routine treatment conditions in HIV infected infants and young children who cannot swallow tablets.</p> <p>Secondary objectives: (1) Document the safety of LPV/r pellets and AZT/3TC or ABC/3TC; (2) Assess the population pharmacokinetics of LPV/r and NRTIs when administered as LPV/r pellets plus AZT/3TC or ABC/3TC; (3) Measure adherence to the new formulation; (4) Evaluate children acceptability of the LPV/r pellets and associated dual NRTIs as well as ease of use by the care giver.</p>
<b>Site(s)</b>	Moi Teaching and Referral Hospital, Uasin Gishu
<b>Project Period</b>	4/14/2016 - ongoing
<b>Sponsor(s)</b>	Drugs for Neglected Diseases initiative (DNDi)
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.
<b>Study Title</b>	.PT4A (Peers and Technology for Adherence, Access, Accountability, and Analytics)
<b>Principal Investigator(s)</b>	Rajesh Vedanthan (New York University)
<b>Collaborator(s)</b>	Sonak Pastakia (Purdue University), Antoinette Schoenthaler (NYU), Andrea Troxel (NYU), Benson Njuguna (MTRH), Jeremiah Laktabai (MTRHI), Imran Manji (MTRH), Ann Mwangi (MTRH), Jonathan Dick (Indiana University), Dustin Duncan (Columbia), Tina Tran (Temple University), Becky Genberg (Johns Hopkins University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	The overall objective of this project is to utilize the PRECEDE-PROCEED framework to conduct transdisciplinary, translational implementation research focused on improving medication adherence for hypertension control. Aim 1: will identify micro- and macro-level contextual factors that might influence the implementation of the PT4A strategy (individual, family, clinician, health system, and environment), using qualitative methods. Aim 2: We will then use a human-centered design approach to refine the PT4A intervention using the findings from Aim 1. Sub-Aim 2.1: will evaluate the intervention for acceptability and appropriateness using focus group discussions with patients, peers, and clinical staff. In Sub-Aim 2.2: we will then conduct a pilot of the intervention and conduct focus group discussions with patients, peers, and clinical staff to evaluate feasibility. We will also evaluate impact on systolic blood pressure, medication adherence, and fidelity of implementation.

<b>Site(s)</b>	Bungoma, Trans Nzoia, Uasin Gishu
<b>Project Period</b>	9/25/2020 - 8/31/2021
<b>Sponsor(s)</b>	NHLBI
<b>Status</b>	Not started -- Study activities have not begun.
<b>Study Title</b>	SAFI (Stigma in AIDS Family Inventory) Validation Study
<b>Principal Investigator(s)</b>	Rachel Vreeman (Mount Sinai)
<b>Collaborator(s)</b>	WinstoneNyandiko (Moi University), Irene Marete (Moi University), Violet Nanyu (Moi University), Hai Liu (Indiana University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	The specific aims for the SAFI validation study were: Aim 1: Identify and modify HIV/AIDS stigma questionnaire items for maximum reliability and content validity to measure perceived, enacted and internalized HIV/A stigma among Kenyan families with HIV-infected children. Aim 2: Assess the validity of the measures of perceived, enacted and internalized H/A stigma compared to independent construct measures including pediatric adherence to therapy and children's physical, psychological and social outcomes. Aim 3: Examine whether disclosure of a child's HIV status reduces perceived, enacted, or internalized stigma for families with disclosed children compared to families with non-disclosed children.
<b>Site(s)</b>	Bungoma, Busia, Moi Teaching and Referral Hospital, Nandi, Trans Nzoia, Uasin Gishu
<b>Project Period</b>	12/17/2013 - 12/31/2015
<b>Sponsor(s)</b>	National Institute of Mental Health
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.
<b>Study Title</b>	Spatial scales of Plasmodium falciparum generations; implications for elimination
<b>Principal Investigator(s)</b>	Andrew Obala (Moi University)

<b>Collaborator(s)</b>	Wendy O'Meara (Duke University), Diana Menya (Moi University)
<b>Study Type</b>	Prospective cohort
<b>Specific Aim(s)</b>	The overall goal is to match infections in malaria-infected mosquitoes to malaria infections in humans in order to understand what persons infected each mosquito and the distance between the donor and the location where the mosquito was trapped. Aim 1: Measure the genetic relatedness of infections within the same household compared to the relatedness of infections at further distances to determine whether this relationship differs in fever 'hotspots' (geographic clusters of high fever incidence) and fever 'coldspots'. Aim 2: Trap malaria mosquito vectors and identify infected mosquitoes to determine the source of the mosquito's infection by sequencing parasites in the mosquito salivary glands and comparing to parasite genotypes in humans.
<b>Site(s)</b>	Bungoma
<b>Project Period</b>	7/1/2019 - 6/30/2021
<b>Sponsor(s)</b>	National Institute of Allergy and Infectious Diseases (NIAID)
<b>Status</b>	Ongoing -- Follow Up Continues. Enrollment has finished but participants are still receiving research-related intervention, interaction, or follow up.

<b>Study Title</b>	Stated Preference Analysis to Refine PMTCT Service Delivery in Kenya (SPARK) study
<b>Principal Investigator(s)</b>	John Humphrey (Indiana University)
<b>Collaborator(s)</b>	Edwin Were, Winstone Nyandiko, Violet Naanyu, Bett Kipchumba, Marsha Alera, Alan McGuire, Beverly Musick, James Carlucci, Constantin Yiannoutsos, Gregory Zimet, Kara Wools-Kaloustian
<b>Study Type</b>	Cross-Sectional
<b>Specific Aim(s)</b>	Aim 1. Identify the relative importance of key PMTCT services according to PPHIV in western Kenya. Aim 2. Explore the influence of various characteristics of PPHIV on their preferences for different PMTCT services.
<b>Site(s)</b>	Busia, Moi Teaching and Referral Hospital, Uasin Gishu
<b>Project Period</b>	6/1/2021 - ongoing
<b>Sponsor(s)</b>	None
<b>Status</b>	Not started -- Study activities have not begun.

<b>Study Title</b>	Strengthening Referral Networks for Management of Hypertension Across the Health System (STRENGTHS)
<b>Principal Investigator(s)</b>	Constantine Olieba Akwanalo (Moi University)
<b>Collaborator(s)</b>	Jemima Kamano, Benson Njuguna, Violet Naanyu, Ann Mwangi, Timothy Mercer, Rajesh Vedanthan, Sonak Pastakia, Jonathan Dick, Makeda Williams
<b>Study Type</b>	Cluster randomized controlled trial
<b>Specific Aim(s)</b>	Aim 1: Evaluate the effectiveness of HIT and peer support on one-year change in SBP and CVD risk reduction. Aim 2: Conduct mediation analysis to evaluate the influence of changes in referral network characteristics on intervention outcomes, and a moderation analysis to evaluate the influence of baseline referral network characteristics on the effectiveness of the intervention. Aim 3: Conduct a process evaluation using the Saunders framework, evaluating key implementation measures related to fidelity, dose delivered, dose received, recruitment, reach, and context. Aim 4: Evaluate the incremental cost-effectiveness of the intervention, in terms of costs per unit decrease in SBP, per percent change in CVD risk score, and per DALY saved.
<b>Site(s)</b>	Bungoma, Busia, Nandi, Trans Nzoia, Uasin Gishu
<b>Project Period</b>	9/1/2017 - 5/31/2022
<b>Sponsor(s)</b>	The National Heart Lung and Blood Institute (NHLBI) Grant Number: U01HL138636
<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.

<b>Study Title</b>	The Effect of Weekly Text Messaging to Improve Retention across the PMTCT Cascade for Pregnant HIV- infected Women: Study Protocol for a Randomized Controlled Trial (WeTel PMTCT)
<b>Principal Investigator(s)</b>	Anna Mia Ekström (Karolinska Institutet)
<b>Collaborator(s)</b>	Edwin Were (Moi University)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	The primary objective is to determine the effectiveness of the WeTel SMS intervention on retention of women living with HIV and their newborns in PMTCT care in urban and rural Kenya. Secondary Objectives 1: To assess adherence to the WeTel SMS intervention among pregnant women and newly

	delivered mothers living with HIV. Objective 2: To determine adherence to single components of PMTCT among pregnant women and newly delivered mothers living with HIV (ARVs, facility-based delivery, early infant HIV testing, and exclusive breastfeeding). Objective 3: To explore facilitators for and barriers to using WelTel SMS in order to inform any improvements on the model for PMTCT among pregnant women and newly delivered mothers living with HIV as well as PMTCT staff. Objective 4: To evaluate costs from a payer's perspective, of the WelTel SMS for retaining women living with HIV and HIV-exposed infants in clinical follow-up until 24 months post-delivery (discharge from PMTCT).
<b>Site(s)</b>	Busia, Kisumu, Moi Teaching and Referral Hospital, Trans Nzoia, Uasin Gishu
<b>Project Period</b>	6/25/2015 - ongoing
<b>Sponsor(s)</b>	Swedish Research Council
<b>Status</b>	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.

<b>Study Title</b>	THE IMPACT OF USING HEMOTYPE SCTM IN SCREENING FOR SICKLE CELL DISEASE IN NEONATES, INFANTS, AND CHILDREN UNDER FIVE YEARS OF AGE IN A RESOURCE LIMITED SETTING
<b>Principal Investigator(s)</b>	Christopher Mwaniki (Duke University)
<b>Collaborator(s)</b>	Festus Njuguna (Moi University), Ann Greist (Indiana Hemophilia and Thrombosis Centre), Chris Roberson (Indiana Hemophilia and Thrombosis Centre)
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: To evaluate the uptake of HSST among immunization population. Aim 2: To evaluate the proportion of those screened with HSST and get followed up through the Hb Electrophoresis. Aim 3: To determine the rate of enrollment of those found to have sickle cell into the comprehensive sickle cell clinic. Aim 4: To evaluate the prevalence of sickle cell among screened children age 5 and below presenting in the immunization clinic at the Homabay county referral hospital.
<b>Site(s)</b>	Homa Bay
<b>Project Period</b>	12/1/2020 - 12/1/2022
<b>Sponsor(s)</b>	None

<b>Status</b>	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.
<b>Study Title</b>	.The Prevalence of and Risk Factors for Non-Alcoholic Fatty Liver Disease in Kenya
<b>Principal Investigator(s)</b>	Fatuma Some (Moi University)
<b>Collaborator(s)</b>	Naga Chalasani, Niharika Samala, Suzanne Goodrich, Mercy Karoney, Alexa Monroy
<b>Study Type</b>	Prospective
<b>Specific Aim(s)</b>	Aim 1: To determine the prevalence of steatosis and hepatic fibrosis in PLHIV and in individuals without HIV infection where diagnosis is based on predefined clinical, laboratory, and imaging criteria. Aim 2: To develop a bio-specimen bank comprised of serum, plasma, and DNA obtained from PLHIV and in individuals without HIV infection to support the evaluation the independent effects of ART, HIV factors, gene variants, and metabolic abnormalities on risk of fatty liver.
<b>Site(s)</b>	Moi Teaching and Referral Hospital
<b>Project Period</b>	3/1/2021 - ongoing
<b>Sponsor(s)</b>	Indiana University
<b>Status</b>	Not started -- Study activities have not begun.
<b>Study Title</b>	.Virologic Treatment Failure and Drug Resistance in HIV-infected Kenyan Children
<b>Principal Investigator(s)</b>	Rachel Vreeman (Mount Sinai)
<b>Collaborator(s)</b>	Winstone Nyandiko (Moi University), Rami Kantor (Brown University), Samuel Ayaya (Moi University), Joe Hogan (Brown University)
<b>Study Type</b>	Prospective cohort (with additional retrospective analyses)
<b>Specific Aim(s)</b>	Aim 1: Determine prevalence of viral failure and examine resistance mutations among a retrospective study cohort of 685 prenatally HIV-infected Kenyan children on 1st-line ART. Aim 2: Investigate associations between specific adherence patterns, ART drug levels and other demographic and clinical factors, with viral failure and drug resistance. Aim 3: Study long-term immunologic, virologic and drug resistance outcomes and their associations in prospectively re-enrolled study participants Aim 4: Enhance analyses of viral failure, drug resistance accumulation and associated demographic and clinical factors by



	examining the longitudinal banked samples available for a subset of the study cohort (n=327). Aim 5: Develop a data-driven intervention algorithm to identify children at risk for viral failure and resistance.
Site(s)	Bungoma, Moi Teaching and Referral Hospital, Trans Nzoia, Uasin Gishu
Project Period	8/2/2017 - 7/31/2020
Sponsor(s)	NIH
Status	Ongoing -- Data Analysis Only. Participants have completed all research-related intervention, interaction, and follow up. Research activities are limited to data analysis.



Study Title	World Bleeding Disorders Registry (WBDR)
Principal Investigator(s)	Festus Njuguna (Moi University)
Collaborator(s)	Donna Coffin (World Federation of Hemophilia), Glenn Pierce (World Federation of Hemophilia), Alain Baumann (World Federation of Hemophilia), Festus Njuguna (Moi University)
Study Type	Prospective
Specific Aim(s)	WBDR will aim to address the following: Aim 1: Identify gaps in evidence related to diagnosis, access to care, treatment, and outcomes in patients that include: <ul style="list-style-type: none"> <li>• Comparative evaluation of preventative treatment regimens (e.g., prophylaxis)</li> <li>• Identification of high-risk populations</li> <li>• Inhibitors and other complications of BD</li> <li>• Trends in treatment patterns over time</li> <li>• Discrepancies in quality of care</li> <li>• Data on factor utilization.</li> </ul> Aim 2: Collection of data to support advocacy initiatives aimed at improving diagnosis and access to care around the world, such as: <ul style="list-style-type: none"> <li>• Burden of disease data:</li> <li>• Annual bleeding rate</li> <li>• Functional assessment</li> <li>• Hospitalization</li> <li>• Lost days of school/work</li> <li>• Educational/employment attainment</li> <li>• Between country discrepancies in factor usage.</li> </ul>
Site(s)	-
Project Period	9/6/2018 - ongoing
Sponsor(s)	None
Status	Ongoing -- Open to Enrollment. Participants are being enrolled and receiving research-related intervention, interaction, or follow up.